åçåŽåçå»æ¿å±é·éç¥ïŒå»æ¿çº 0430第 1å·ïŒ
ãå»çã¹ã¿ããã®ååã»é£æºã«ããããŒã å»çã®æšé²ã«ã€ããŠã
æ¥æ¬ç é¢è¬å€åž«äŒã«ãã解éãšå®è·µäºäŸ
ïŒVer.2.0ïŒ
å¹³æ 26幎 4æ 12æ¥
äžè¬ç€Ÿå£æ³äºº æ¥æ¬ç é¢è¬å€åž«äŒ
â ïŒã¯ããã«
å»çã®æ¥æ¿ãªé²å±ã«äŒŽããããããé«ãå°éæ§ããã€å»çåŸäºè ãååããæ£è äžå¿ã®å»çãå®è·µ
ããããŒã å»çãæšé²ããããšã®éèŠæ§ã匷ãèªèãããããã«ãªã£ããããããç¶æ³ãèæ¯ã«ãå
çåŽåçã«èšçœ®ããããããŒã å»çæšé²ã«é¢ããæ€èšäŒãã®å ±åæžïŒå¹³æ 22 幎 3 æ 19 æ¥ïŒãèžãŸã
ãŠãå¹³æ 22 幎 4 æ 30 æ¥ä»ã®åçåŽåçå»æ¿å±é·éç¥ãå»çã¹ã¿ããã®ååã»é£æºã«ããããŒã å»ç
ã®æšé²ã«ã€ããŠããçºåºãããã
ãã®äžã§ãå€çš®å€æ§ãªå»çã¹ã¿ããããåã ã®é«ãå°éæ§ãåæãšããç®çãšæ å ±ãå ±æããæ¥å
ãåæ ãããšãšãã«ãäºãã«é£æºã»è£å®ãåããæ£è ã®ç¶æ³ã«ç確ã«å¯Ÿå¿ããå»çãæäŸããããŒã
å»çãïŒå»æ¿å±é·éç¥ãåæïŒã匷ãæ±ããããŠãããã€ãŸããå»çã¹ã¿ããã®ååãªã³ãã¥ãã±ãŒ
ã·ã§ã³ãåæãšããããŒã å»çã«è¬å€åž«ãç©æ¥µçã«åç»ããè¬ã®å°é家ãšããŠå»çã«è²¢ç®ããããšã
éèŠã§ãããäžèšã«ç€ºãæ¥æ¬ç é¢è¬å€åž«äŒïŒä»¥äžãæ¥ç è¬ïŒã®å»æ¿å±é·éç¥ã«å¯Ÿãã解éãšå®è·µäºäŸ
ã«ãããŠããã®ãããªããŒã å»çã®èãã«åºã¥ããŠå®æœããããšãåæãšãªã£ãŠããã
éç¥ã§ã¯ããå»çã®è³ªã®åäžåã³å»çå®å šã®ç¢ºä¿ã®èŠ³ç¹ãããããŒã å»çã«ãããŠè¬å€ã®å°é家ã§
ããè¬å€åž«ãäž»äœçã«è¬ç©çæ³ã«åå ããããšãéåžžã«æçã§ããããšæèšããããšãšãã«ãè¬å€åž«
ãåãçµãã¹ã 9é ç®ã®æ¥åäŸãæèšãããŠããã
ãã®éç¥ã¯ãåçåŽåçãçŸè¡æ³ïŒå»çæ³ãå»åž«æ³ãè¬å€åž«æ³çïŒäžã§å®æœå¯èœãªè¬å€åž«æ¥åã瀺
ãããã®ã§ãããå°ãªããšãããã«ç€ºãããæ¥åã¯ä»åŸã®è¬å€åž«æšæºæ¥åãšããŠäœçœ®ã¥ããããããš
ãäºæ³ãããããŸãããããæ¥åã¯ãå°åå»çã®éèŠæ§ãé«ãŸã£ãŠããçŸåšãç é¢ã»èšºçæã°ããã§
ã¯ãªããå°åå»çããšãããåšå® å»çã«ãããŠã圹å²ãä»åŸãŸããŸãéèŠã«ãªãããšãæå³ããŠããã
ç é¢ã»èšºçæã«ãããããŒã å»çã®å®æœã«ããã£ãŠã¯ãåå»çæ©é¢ã«ãããŠæ¥åå 容ã«èŠåã£ãè¬
å€åž«ã®é 眮ãåæãšãªããæ¥ç è¬ãšããŠãè¬å€åž«æ°ã®æ¡å ã¯å«ç·ã®èª²é¡ãšèªèããŠãããåå»çæ©é¢
ã«ãããŠããæ¥åã®åçåã»å¹çåã«åãçµã¿ãåŸæ¥ã®æ¥åäœå¶ã®èŠçŽããè¡ããªã©ãç æ£ã«è¬å€åž«
ãå¹çããåžžé§ãããããã®å¯Ÿçãè¬ããããŒã å»çå®çŸã®ããã«æ倧éã®åªåããé¡ããããã®ã§
ããã
äžè¿°ã®å»æ¿å±é·éç¥ã«èšèŒãããæ¥åäŸã«ã€ããŠãæ¥åžžã®æ¥åã«ãããŠå ·äœåããããã«ãæ¥ç è¬
ãšããŠã®èŠè§£ããŸãšãããã®ã解éããšãå ·äœäŸã(Ver1.0)ãšããŠãŸãšããæ¢ã«ç€ºããŠããã
ä»è¬ããã®åŸã®å ·äœçãªæ¥åã®å±éãéã¿ãæ¥ç è¬ã®æ°ããªèŠè§£ãšããã«ãå ·äœçãªå®è·µå®äŸããŸ
ãšãããã®ãå ãããæ確ãªèšåºçãªã¢ãŠãã«ã ãåŸãããããè¬å€åž«æ¥åã®ãããªã質çåäžã«å
ããå±éã匷ã埡é¡ããããã®ã§ããã
1
â ¡. éç¥ã«èšèŒãããæ¥åäŸã®è§£éãšå ·äœäŸ
ïŒïŒè¬å€åž«ãç©æ¥µçã«æŽ»çšããããšãå¯èœãªæ¥å
æ¥åäŸ-â
è¬å€ã®çš®é¡ãæäžéãæäžæ¹æ³ãæäžæéçã®å€æŽãæ€æ»ã®ãªãŒãã«ã€ããŠãå»åž«ã»è¬å€åž«çã«
ããäºåã«äœæã»åæããããããã³ãŒã«ã«åºã¥ããå°éçç¥èŠã®æŽ»çšãéããŠãå»åž«çãšåå
ããŠå®æœããããšã
ã解éã
æ§ã ãªçŸæ£ã«å¯Ÿããè¬ç©çæ³ã®åºæ¬æ¹éããå»åž«ãè¬å€åž«ããã³çè·åž«ãªã©ã®å»çããŒã ã®ã¡ã³ã
ãŒéã§æ€èšã»åæãããå æ¬çãªãããã³ãŒã«ïŒã¬ãžã¡ã³ãæ²»çèšç»ïŒãããã¯åã ã®æ£è ã«å¯Ÿãã
ãããã³ãŒã«ãäœæãããããã®å Žåã«ã¯ããã®ãããã³ãŒã«ã«åŸã£ãŠãæé©ãªæäžéã®èšå®ãé節
ãªå¯äœçšçºçŸãé²æ¢ããããã«ãèšåºæ€æ»ãè¬ç©è¡äžæ¿åºŠã¢ãã¿ãªã³ã°ïŒTDMïŒãé©åã«èšç»ã»å®æœãã
ãã®çµæã«ã€ããŠè§£æã»è©äŸ¡ãè¡ãããã®ä»ã®æ å ±ãšãšãã«ããšããã³ã¹ã«åºã¥ããè¬ç©æäžèšç»ã
ç«æ¡ãããããã«ãå¿ èŠã«å¿ããŠæé©ãªåŠæ¹ïŒè¬å€ã®çš®é¡ãæäžéãæäžæ¹æ³ãæäžæéçïŒã«é æ»
ãªãå€æŽãããšãšãã«ãéããã«ããŒã ã®ã¡ã³ããŒãšã«ã³ãã¡ã¬ã³ã¹ãé»è©±ïŒé¢å ããŒã¿ã«ïŒã
ã«ã«ãïŒé»åïŒãžã®èšèŒãªã©ã«ããååãªæ å ±äº€æãå³ãããªãããããã³ãŒã«ã¯ãååŠäŒã®æ²»çã¬
ã€ãã©ã€ã³ãåèã«ããŠäœæããããšãæãŸããããŸãããããã³ãŒã«ã«ã¯ãåŠæ¹å 容ã®å€æŽãæ€æ»
ã TDM ã®ãªãŒããªã©ãè¬å€åž«ãå®æœããæ¥åå 容ãšãã®ç¯å²ãæ確ã«ããããšãå ããŠããã¹å§å¡äŒ
çè¬ç©é©æ£äœ¿çšã«ããããåå§å¡äŒã«ã¯ç©æ¥µçã«åå ããè¬ç©çæ³ã®é©æ£åã®ããã®ã·ã¹ãã æ§ç¯ã«
é¢äžããã
ã解éã®å ·äœäŸã
1. æ·»ä»ææžã®èŠåæ¬ã«ãå®æçãªæ€æ»ã®å®æœããæ±ããããŠããå»è¬åã«ã€ããŠã¯ããå®æçãã®ç€º
ãäºæãå ·äœçã«ããå»è¬åã®å®å šäœ¿çšã®ããã®æ¥åæé æžãã«èšèŒããã調å€æã«å®æçãªæ€æ»ã®
å®æœç¶æ³ãé©å®ææ¡ããæ€æ»ãæªå®æœã®å Žåã«ã€ããŠã¯å»åž«ãšååããŠè¬å€åž«ãæ€æ»ãªãŒããè¡ãã
ãã«åªããã
2. ããååŠçæ³ã«ãããå¯äœçšå¯Ÿçã¯ãæ²»çã®æå¹æ§ãé«ããå®å šæ§ã確ä¿ããäžã§æ¥µããŠéèŠã§ã
ããæ£è ã®ããååŠçæ³ã®æ¹éã決å®ããéã«ãå¯äœçšå¯Ÿçã«ã€ããŠãåºæ¬æ¹éã決å®ãããäŸãã°ã
æ²»çéå§åŸã«ã匷ãååãªã©ã®å¯äœçšãèµ·ãã£ãå Žåã«ã¯ãè¬å€åž«ããå¶åè¬ã®è¿œå ãå€æŽãå»åž«ãš
ååããŠè¡ãããšãåºæ¬æ¹éã«å ããã
3. å¶åè¬ã®äœ¿çšåºæºãäœæãããã®åºæºã«æ²¿ã£ãŠé©åã«éçšãããå¶åè¬ã¯ã¬ãžã¡ã³ã«ãã£ãŠäœ¿ãå
ããåºæºãäœæãããæ£è ã«å¯äœçšãçºçŸããå Žåãå¶åè¬åŠæ¹ãè¿œå ãå€æŽãããå Žåãéããã«
å»çããŒã ã®ã¡ã³ããŒã«äŒéããã
2
4. ããååŠçæ³ã¬ãžã¡ã³ããšã«äºåã«æ±ºããããéæ»é ç®ã«åºã¥ãã調補åã«æããå€åŠæ¹ã®åŠ¥åœ
æ§(äŒè¬æéã»æäžéã»äœµçšè¬ç)ã確èªããç矩ãããã°å»åž«ã«åãåãããè¡ãããŸããB åèçæ
åæäœæ€æ»ã®æç¡ã確èªããå¿ èŠãããã°å®æçã«ãŠã€ã«ã¹éã®ç¢ºèªãå»åž«ã«äŸé Œããã
5. è¡æ¶²æªæ§è «çã«å¯ŸããŠååååŠçæ³ãè¡ãå Žåãè «ç厩å£çå矀ã®ãªã¹ã¯è©äŸ¡ãå»åž«ãšå ±ã«è¡ãã
ã¬ãžã¡ã³ã«åºã¥ãæé©ãªåŠæ¹ãé 延ãªãææ¡ããããã®ããã«ãå¿ èŠã«å¿ããŠååŠçæ³éå§åã®çå
åŠæ€æ»ã«æ€æ»é ç®ã®è¿œå ãææ¡ããã
6. åæããè¬ã®ç¹åŸŽçãªå¯äœçšãã¢ãã¿ãªã³ã°ããããã«ãé«ãªã³è¡çãèç³èœç°åžžã䟿ç§ãªã©ã®
ã¢ãã¿ãªã³ã°é ç®ãæ確åããã¢ãã¿ãªã³ã°ã®é »åºŠãå¯äœçšãçºçŸããå Žåã®å¯ŸåŠæ¹æ³ãããŒã ã§å
è°ã決å®ãããæ€æ»ã®çµæãç°åžžãèªããããå Žåã¯äºåã«åè°ã»æ±ºå®ãããŠããæ¯æçæ³è¬ã®è¿œå
ãªãŒããéããã«å»åž«ãšåè°ããŠå®æœããã
7. äºåã«äœæãããã¬ãžã¡ã³ã«åºã¥ããŠããã©ããç³»æããè¬ã®æäžãåããæ£è ã«å¯ŸããŠéæç
åå¿ã®äºé²å¯Ÿçããã³ã¢ãã¿ãªã³ã°ãå»åž«ãçè·åž«ãšååã§å®æœãããç¹ã« CBDCA ã L-OHP ã®åæäž
ãåããæ£è ã环ç©æäžéãå€ãæ£è ã¯éæçããã€ãªã¹ã¯ã§ãããããåæè¬åŒ·åã®ææ¡(æãã¹ã¿
ãã³å€ã H2æ®æè¬ã®åæè¬ãã¹ããã€ãæäžéã®å¢éç)ãç¹æ»Žæé延é·ã®ææ¡ãå»åž«ã«è¡ãçºçŸãªã¹
ã¯ã®æå°åã«åªãããæäžéå§åŸã¯ãéæçåå¿ã®åæçç¶(ããã¿ãåŒåžèŠãç®ç¹ãåæ°ãªã©)ãã
ã€ã¿ã«ãµã€ã³ã®ç¢ºèªãè¡ããç°åžžãèªããå Žåã¯éããã«å»åž«ã«å ±åã察å¿ããã
8. ç¶æéæãè¡ã£ãŠããæ£è ã®ããã©ã«ä»£è¬ç°åžžïŒCKD-MBDïŒã«ãããŠãå»åž«ãšè¬å€åž«çãååããŠ
æ£è ã«é©ããéæ管çãããã³ãŒã«ãäœæããããŸããè¬å€åž«ã¯å®æçã«è¡ãããè¡æ¶²æ€æ»ã®ããŒã¿
ã確èªãããããã³ãŒã«ã«åŸã£ãŠè¬å€ã®å¢æžãæ€æ»ãªãŒãã®è¿œå ãååã§è¡ãã
9. 粟ç¥ç§è¬ç©çæ³ã§ã¯ãå€å€å€§éåŠæ¹ã®é©æ£åãå¯äœçšé²æ¢ã®èŠ³ç¹ãããå»åž«ãšååããŠè¬ç©ãã
ãã³ãŒã«ãäœæããããŸããæè¬ã¢ããã¢ã©ã³ã¹ã®åäžãç®çãšããåãçµã¿ãšããŠãå¯äœçšã®ç¢ºèª
ã DAI-10ïŒDrug Attitude Inventory-10ïŒãªã©ãå®æœãããããã®çµæãæ£è æèŠãèžãŸããè¬ç©æ
äžéãæäžæ¹æ³ãæäžæéãå€åœ¢ãªã©ã«é¢ããåŠæ¹æ€èšãå»åž«ãšååããŠè¡ãã
10. æ粟ç¥ç è¬ã®æäžå¯Ÿè±¡ãšãªãæ£è ã«ãããŠã¯ãå¥åº·çãªç掻ç¿æ £ã®ç¶æãé£ãããšãã£ãããã®
çŸæ£æ£è ã®ç¹æ§ãæ粟ç¥ç è¬ã®å¯äœçšã«ãã代è¬ç°åžžãªã©ã®èŠå ã«ãã£ãŠãç³ã»è質代è¬ç°åžžãæ¥ã
ãããããã®ããã身äœçŸæ£ãå«ããç æ 管çãéèŠãšãªããè¡ç³å€ãäœéãBMI ã®å€åãè¡ç³å€ãè¡
äžè質ãªã©ã®ããŸããŸãªèšåºæ€æ»å€ãæ®æ®µã®é£ç掻ãªã©ã®ç¶æ³ãèžãŸããé©åãªè¬ç©çæ³ãå»åž«ãšå
åããŠè¡ãã
3
11. æ²»çæµææ§çµ±å倱調çæ²»çè¬ã§ããã¯ãã¶ãã³ã®äœ¿çšã«ãããŠã¯ãéå§æã«æ£è ã®é©æ Œæ§ããã³
åæååŸã®ç¢ºèªãè¡ãããã®åŸã¯é節ãªå¯äœçšçºçŸã®ãã§ãã¯ã®ããã®è¡æ¶²æ€æ»ïŒçœè¡çæ°ã奜äžç
æ°ãããã³è¡ç³å€ã¢ãã¿ãªã³ã°çïŒçããããã³ãŒã«ã«åºã¥ããªãŒããã䜿çšèŠå®éµå®ã«åªãããã
ããŠãæ£è ã® QOL 䞊ã³ã«ã¢ããã¢ã©ã³ã¹ãäœäžãããå¯äœçšã®æ©æçºèŠã«åªããé©åãªæäžéãšãªã
ããã«ããã
12. äºåã«äœæããããããã³ãŒã«ã«åºã¥ããæè¡äºå®è ã«å¯ŸããŠãåžžçšè¬ã確èªããæååºè¬ã»ç³
å°¿ç æ²»çè¬ã»åŸªç°åšç³»è¬å€çã®åŠæ¹ã«çæããèšåºæ€æ»å€ããã€ã¿ã«ãµã€ã³ã確èªã®äžãé©åãªåšè¡
æ管çãå»åž«ãšååããŠå®æœããã
13. æ¥æ§æè¡æ 溶解çæ³ã®å¯Ÿè±¡ãšãªãããè³æ¢å¡ææ¥æ£è ã«å¯ŸããŠãåã ã®æ£è ã«ãã£ãæäžéã»æµ
éçãèšç®ããŠå»åž«ã«ææ¡ããéããã«è¬å€èª¿è£œãè¡ãã
14. æ§ã ãªé害ããã£ãé«éœ¢è ã«å¯Ÿããæ£è ã®å¥äžèœåãããŒã ã§è©äŸ¡ããå¥äžç¶æ ã«å¿ããŠå€åœ¢ã
å€æŽããŸãã¯ãçµç®¡æ é€ã®æ£è ã«å¯ŸããŠã¯äžè¬ã«é©ããå€åœ¢ã«å€æŽãããªã©ãåŠæ¹è¬ã®å€æŽã»ä¿®æ£ã
å»åž«çãšååã§è¡ãã¢ããã¢ã©ã³ã¹ã®æ¹åãªãã³ã«è¬åŠçã±ã¢ã®åäžãå³ãã
15. éå¡æ§åè硬åçã§äžè¢ã®çŒçã³ã³ãããŒã«ãäžè¯ãªæ£è ã«å¯ŸããŠã䜿çšããé®çè¬ãæäžéã
䜵çšè¬çããããããå»åž«çãšãããã³ãŒã«ãäœæãããé®çè¬äœ¿çšã«ããå¯äœçšã«ã€ããŠç¢ºèªãã
ãšãšãã«ãå®æçã«çŒçè©äŸ¡ãè¡ããã³ã³ãããŒã«äžè¯ã§ããã°ãé®çå€ã®å¢éçãå»åž«ãšååããŠ
å®æœããã
æ¥åäŸ-â¡
è¬å€éžæãæäžéãæäžæ¹æ³ãæäžæéçã«ã€ããŠãå»åž«ã«å¯Ÿããç©æ¥µçã«åŠæ¹ãææ¡ããã
ãšã
ã解éã
æ£è ç¶æ³ïŒçŸæ£åãè ããã³èæ©èœãèšåºæ€æ»å€ããã€ã¿ã«ãµã€ã³ãèªä»èŠçç¶ãè¬ç©è¡äžæ¿åºŠã
ã¢ããã¢ã©ã³ã¹çïŒãä»æœèšã§åŠæ¹ãããè¬å€ïŒæåè¬ïŒãªã©ãè¬å€åž«ãã¢ã»ã¹ã¡ã³ãããŠãè¬ç©ç
æ³å šäœïŒè¬å€éžæãæäžéãæäžæ¹æ³ãæäžæéãªã©ïŒã«ã€ããŠå€æããæé©ãªåŠæ¹ææ¡ãç©æ¥µçã«
è¡ãã
ã解éã®å ·äœäŸã
1. æ£è ã®è æ©èœã確èªããæç®çããã®æ å ±ç¢ºèªåŸã«æäžéã®å€æŽãå¿ èŠãšå€æããå Žåãå»åž«ãž
4
åŠæ¹ææ¡ãè¡ããåŠæ¹å€æŽåŸã®å¹æã»å¯äœçšã®ã¢ãã¿ãªã³ã°ãå®æœããããŸããæ£è ãžã®è æ¯æ§ãæ
ããå¯èœæ§ãããè¬å€ãåŠæ¹ãããŠããå Žåã¯è æ©èœãžåœ±é¿ãå°ãªã代æ¿è¬ã®ææ¡ãå»åž«ãžè¡ãã
2. 泚å°è¬å人ã»ããã®éã«ã泚å°ããã«é¢é£æ€æ»å€ããã³è¬æŽã衚瀺ãããªã©ã®æ段ãè¬ãããšãš
ãã«ãé¢é£ããæ€æ»å€ãæäžéãæäžééã®ç¢ºèªãè¡ããçšé調ç¯ãæäžã¹ã±ãžã¥ãŒã«ã«åé¡ããã
ã°å»åž«ã«åŠæ¹å€æŽãææ¡ããã
3. ããååŠçæ³ã«ãããŠé©çšãããã¬ãžã¡ã³ã確èªããç»é²ãããŠããã¬ãžã¡ã³ãšç°ãªãè¬å€ãçš
æ³ã»çšéã§åŠæ¹ãããŠããå Žåã«ã¯å»åž«ãžç¢ºèªããè¬å€åž«ãé©åãªè¬å€ã®ææ¡ãè¡ãã
4. ååŠçæ³æœè¡æ£è ã«å¯ŸããŠãå¯äœçšçç¶ãã¢ãã¿ãŒããååã奜äžçæžå°ã貧è¡ãåºè¡ãæ足ç
å矀ãçºç¹ã䟿ç§ãå£å çãè¡ç®¡ççã®å€æ§ãªå¯äœçšãæ©æã«çºèŠããããåªããå¯äœçšæ¹åã®ãã
ã®æ¯æçæ³ãšããŠå¶åè¬ãG-CSF補å€ãè»èãå³åœè¬çã®é©åãªåŠæ¹ãææ¡ããã
5. æããå€ãã¹ããã€ãæäžæ£è ãªã©ã§å¯äœçšåé¿ã®ããã®åæè¬ã®åŠæ¹ã®æç¡ã確èªããå¿ èŠãªåŠ
æ¹ããããŠããªããã°åŠæ¹ææ¡ãè¡ãããŸããäžèŠãªåŠæ¹ãç¶ç¶ãããŠããã°äžæ¢ææ¡ãè¡ãã
6. è¬å€åž«ã¯ãç·©åã±ã¢ç æ£ã§ãæ£è ã®çã¿ãå¯äœçšã®çšåºŠã芳å¯ããæ¥ã«åŒ·ãçã¿ãçããæ£è ã«å¯Ÿ
ããèšæè¿œå æäžïŒã¬ã¹ãã¥ãŒããŒãºïŒãå¯äœçšãªã©ã«ããçŒçã³ã³ãããŒã«ãäžèœãšãªã£ãå Žåã®
ä»ã®ãªããªã€ãé®çå€ãžã®å€æŽïŒãªããªã€ãããŒããŒã·ã§ã³ïŒãåæ°ã䟿ç§ãç æ°ãããåŠçå¯äœçš
çç¶ã軜æžããããã®åŠæ¹ãææ¡ããã
7. ç·©åã±ã¢ããŒã ã«ãããŠãå€æ¥æ£è ã«å¯ŸããŠã¯å»åž«ã®èšºå¯ã«ç«ã¡äŒããå ¥é¢æ£è ã«å¯ŸããŠã¯ã©ãŠã³
ãã«åå ããçŒçç·©åããã¥ã¢ã«ã«åºã¥ãé©åã«çŒç管çãè¡ããããå»åž«ã«åŠæ¹ææ¡ãè¡ãããã
ã«ãé®çè£å©è¬ã®äœ¿çšããã¥ã¢ã«ãäœæããå®æœç®¡çãè¡ãã
8. æ£è ã®è¿ãåç°ãå°¿çããã®èæ§èæ€åºç¶æ³ãèµ·çèã®åå®ãè¬å€æåæ§ã®ç¢ºèªãé¢å ã«ããã
æèè¬äœ¿çšç¶æ³ïŒæèè¬ã®äœ¿çšå®æ . 䜿çšå¶éãæ¡çšè¬ã®è©äŸ¡ãèæ§èã®åºçŸç¶æ³çïŒããã§ãã¯ãã
é©åãã€èæ§èã®çºçãé²ãæèè¬ã®éžæãæäžéãæäžæéçã®åŠæ¹ãææ¡ããã
9. ææçæ²»çã«çšããããæèè¬ã«ã€ããŠãææçå¥ã®æšæºçæäžãããã³ãŒã«ããé¢å ã®ææ察
çå§å¡äŒãããã¯å»åž«ã»è¬å€åž«ãäœæãããè¬å€åž«ã¯ãæèè¬ã®å¹æã»å¯äœçšã«ã€ããŠã¢ãã¿ãŒããŠã
èçš®ãè¬å€èæ§ãªã©å¿ èŠãªæ€æ»ããªãŒããããããã«ãåã ã®æ£è ã® TDMïŒPKïŒPD ãã©ã¡ãŒã¿ã®ç®åº
ãèæ ®ïŒãäœå åæ çã®ãšããã³ã¹ã«åºã¥ããŠã䜿çšè¬å€ãæäžéã®å€æŽã泚å°å€ããçµå£å€ãžã®å€
æŽææã«ã€ããŠææ¡ããã
5
10. ãã³ãŸãžã¢ãŒãã³ç³»ç¡ç è¬ãæäžå®è¬ãªã©ã«ã€ããŠãéè€æçšãé«çšéã»æŒ«ç¶æäžãè¡ãããŠã
ãªãã確èªããå¿ èŠã«å¿ãããããã®è¬ç©æäžæ£è ã«ã€ããŠãå»åž«ã«å¯ŸããŠæžéã»äžæ¢çã®åŠæ¹å€æŽã
é¢è±çç¶ãªã©ã軜æžããããã®åŠæ¹å€æŽãææ¡ããã
11. çµ±å倱調çã«ãããè¬ç©çæ³ã«ãããŠã¯ãæ粟ç¥ç è¬ã®å€å€å€§éåŠæ¹ãåžžæ åããŠããããã®ã
ãéäœå€è·¯çç¶ãé«ããã©ã¯ãã³è¡çã䟿ç§ãéé®éãªã©å€å²ã«ãããå¯äœçšãçºçŸããŠããããã
ãã®æ£è ã«å¯ŸããŠãå€å€å€§éåŠæ¹ã«è³ã£ãçµç·¯ãææ¡ããæ£è ã®çç¶ããã³å¯äœçšãèªç¥æ©èœãªã©ã®
è©äŸ¡ãè¡ããè¬å€æ°ã®æžå°ããã³æžéã«åããåŠæ¹å€æŽãææ¡ããã
12. æ粟ç¥ç è¬ãïŒå€ä»¥äžäœ¿çšããŠããæ£è ããã³ãŸãžã¢ãŒãã³ç³»è¬ç©ãïŒçš®é¡ä»¥äžæçšããŠããæ£
è ã«ã€ããŠãåŠæ¹è¬å€ã®ã¯ãã«ããããžã³æç®ããžã¢ãŒãã æç®ã«ããæäžéã®è©äŸ¡ãè¡ããåŠæ¹å»
ã«ãã£ãŒãããã¯ãããšãšãã«ãæžéã«é¢ããåŠæ¹èšç»ãç«æ¡ããå»åž«ãšååããŠç²Ÿç¥çç¶ãæžéã«
䌎ãé¢è±çç¶ãªã©ãã¢ãã¿ãªã³ã°ããªããæé©ãªè¬ç©æ²»çã«åªããã
13. èªç¥çã® BPSDïŒèªç¥çã®è¡åã»å¿ççç¶ïŒã«å¯Ÿããå粟ç¥è¬ã®äœ¿çšç¶ç¶ã«ã€ããŠã¯ã挫ç¶æäžã
äºé²ããããã«ããªã¹ã¯ãšãããã£ãããååã«æ€èšããããã§ãå®æçã«åŠæ¹å 容ã®èŠçŽããè¡ãã
å»åž«ã«åŠæ¹ææ¡ãè¡ãã
14. åæ¯æ²»çã«ãããŠäœ¿çšãããåžå ¥å€ã¯ã補åã«ãã£ãŠåžå ¥æ¹æ³ãç°ãªããæ£ããåžå ¥ã§ããªãå Ž
åãå¹æãäžååã«ãªãããšããããäºåã«å»åž«ãšåè°ãäœæããæ²»çãããã³ãŒã«ã«åºã¥ããæ£è
ã®åžå ¥ææãæå°ã»è©äŸ¡ããããŸããåŒæ°æµéã®æž¬å®çµæããã䜿çšããŠãããã©ã€ããŠããŒåžå ¥è£œ
å€çã®äœ¿çšã劥åœãã©ããå€å®ãè¡ããå¿ èŠã«å¿ãè¬å€ã®å€æŽãææ¡ããã
15. 耥ç¡æ²»çã§ã¯ã耥ç¡ã®ç¶æ ããã§ãã¯ããŠãå€çšè¬å€çš®é¡ã®éžæãå¡åžéã®å€æŽãåµé¢ã®ç§»åã
èæ ®ã«å ¥ããæäžæ¹æ³ïŒç¹ã«å€§ããªè€¥ç¡ã«ã¯ãåµé¢ã®åºå®ãè¡ã£ãäžã§å€çšå€ã®å¡åžãè¡ãããšïŒã
æ²»çç¶æ ããæäžæéãå€æŽãããªã©ã®åŠæ¹ãææ¡ããã
16. ICUïŒéäžæ²»ç宀ïŒæ åœè¬å€åž«ã¯ãæ£è ã®ç¶æ ãææ¡ããäžã§å»åž«ãšååããŠæ£è ã®èº«äœæèŠãèš
åºæ€æ»å€ãç»åçãã¢ãã¿ãŒãã䜿çšè¬å€ãç¹æ»Žé床ãç¹æ»Žã«ãŒãã泚å°å€ã®é åå€åãæäžéã®èª¿
ç¯çã®åŠæ¹ãææ¡ããã
17. NST çã®ããŒã å»çã掻çšãç æ£è¬å€åž«ã¯ã 茞液ã»çµè žæ é€ã§å®æœãããŠããæ£è ã«å¯ŸããŠãæ°Ž
åã»é»è§£è³ªç®¡çãé©åã«è¡ããå šèº«ç¶æ ãè©äŸ¡ããæ£åžžç¶æ ããéžè±ããŠãããšå€æãããå Žåã«ã¯
åŠæ¹ã®å€æŽã»è¿œå ãªã©ãææ¡ããã
6
18. è³æ¢å¡çºçåŸã¯ãå¥äžæ©èœãäœäžãå¥äžæ§èºçã®ãªã¹ã¯ãé«ãŸããããåºæ¥ãéãå£è å 厩å£é
çã®å¥äžããããè¬å€ãåŠæ¹ææ¡ãæ£è ãžã®æè¬æ¯æŽãå»åž«ãžã®åŠæ¹ææ¡ãè¡ããé©åãªå€åœ¢ãç¡ã
å Žåã¯å¥äžè£å©å€ããšãã¿å€ã®äœ¿çšã«ã€ããŠææ¡ãããå¥äžæ§èºçãç¹°ãè¿ãå Žåã¯ãæèã¬ãã«ã
äœäžãããè¬å€ãåŸæ¶²åæ³ãæžå°ãããè¬å€ã®äžæ¢ã»æžéãæ€èšãææ¡ãããããã«ãå¥äžåå°ãä¿
ãè¬å€ã®è¿œå ã«ã€ããŠåŠæ¹ææ¡ãè¡ã誀å¥ã®ãªã¹ã¯ãåé¿ã«åªããã
19. å± å® çé€ç®¡çæå°ã蚪åè¬å€ç®¡çæå°ãªã©ã§è¬å€åž«ãæ£è ã®å± å® ã蚪åããéããããã³ãŒã«ã«
åºã¥ããŠãè¬å€ã®å¹æã»å¯äœçšã®ãã§ãã¯ãæ£è ç¶æ ã®ã¢ãã¿ãªã³ã°ãªã©ãåæ¡ããŠãå»åž«ã«é£çµ¡ã®
äžãæè¬ç¶ç¶ãå¯èœãªå€åœ¢ã®éžæãæäžæéãæäžéã®æžéã»äžæ¢çã®å€æŽãè¡ããšãšãã«ãå»åž«ã
çè·åž«ãšç·å¯ãªé£æºããšãã
æ¥åäŸ-â¢
è¬ç©æ²»çãåããŠããæ£è ïŒåšå® ã®æ£è ãå«ãïŒã«å¯Ÿããè¬åŠç管çïŒæ£è ã®å¯äœçšã®ç¶æ³ã®æ
æ¡ãæè¬æå°çïŒãè¡ãããšã
ã解éã
å ¥é¢äžã®æ£è ã ãã§ã¯ãªããå€æ¥æ£è ãåšå® æ£è ãä»è·è人ä¿å¥æœèšãªã©ã®æœèšå ¥æè ãªã©å šãŠã®
è¬ç©çæ³ãåããŠããæ£è ã«å¯ŸããŠãè¬å€åž«ã¯é©åãªè¬ç©æ²»çãšæ£è ã®å¯äœçšã®æ©æçºèŠãšé²æ¢ã®ã
ãã®è¬åŠç管çãè¡ããæ£è ãšã®é¢è«ããã£ãžã«ã«ã¢ã»ã¹ã¡ã³ã[è¡å§ãèæãäœæž©ãåŒåžæ°ãæèã¬
ãã«ãªã©ã®ãã€ã¿ã«ãµã€ã³ïŒåºæ¬ççåœåŸŽåïŒã®ç¢ºèªã«å ããŠãå»åž«ã®äºè§£ãåŸãäžã§ã®æ蚺ãèŽèšºã
å¿é»å³è§£èªãªã©ã®è©äŸ¡]ãã«ã«ãã®ç¢ºèªãå蚺ã»ã«ã³ãã¡ã¬ã³ã¹ãžã®åå çãéããŠæ£è ã®ç¶æ ãææ¡
ããäžã§ãæè¬ããŠããè¬å€ã®è¬åŠç管çæå°ïŒåŠæ¹ãããè¬å€ã®æäžéãæäžæ¹æ³ãæäžé床ãé
è€æäžãçžäºäœçšãé£åãšã®çžäºäœçšãé åå€åãé åçŠå¿çã«é¢ãã確èªãæ£è ã®ç¶æ 芳å¯ãå¹æã
å¯äœçšçã®ç¶æ³ææ¡ãæè¬æå°çïŒãè¡ããè¬å€ã®å¹æãå¯äœçšã®çºçŸãªã©ã«ã€ããŠããŒã ã®ã¡ã³ã
ãŒãšååã«æ å ±ã»æèŠäº€æããŠãåã ã®æ£è ã«æé©ãªåŠæ¹ãææ¡ããã
ã解éã®å ·äœäŸã
1. å ¥é¢æ£è ã«å¯ŸããŠæè¬æå°ãè¡ãéã«ã¯ãå¯äœçšçºçŸæã«æ©æã«çºèŠã§ããããåæçç¶ã«ã€ããŠ
説æãè¡ãããŸããé åå€åãçžäºäœçšã確èªããå¿ èŠã«å¿ããŠå»åž«ã«ãã£ãŒãããã¯ãè¡ãã
2. å¥äžå°é£æ£è ããã³èããæ£è ã«ãããŠãè¬åŠç管çãä»ããŠãè¬å€ã®å€åœ¢ãæäžæ¹æ³ã®å¯åŠããª
ã©ãå«ããæ å ±åéã«åªããçµæãå»åž«ã«ãã£ãŒãããã¯ããå¿ èŠã«å¿ãçšæ³çšéãå€åœ¢ã®å€æŽçã®
ææ¡ãè¡ãã
7
3. æ£è ã®éé¢ã«éããŠã¯ãå¯äœçšã®åæçç¶ãšçç¶ãåºçŸãããšãã®å¯Ÿå¿ãç·æ¥ã«å»çæ©é¢ãå蚺
ããå¿ èŠãããã®ã¯ã©ããªæããªã©ã説æããæ£è èªããå¯äœçšãåé¿ã§ããããæå°ããããŸãã
å ¥é¢äžã®è¬ç©çæ³ãå¯äœçšç¶æ³çãéé¢æãµããªãŒã«èšèŒããéé¢åŸã®åšå® å»çæ åœè ïŒãããã€ã
å»ãã±ã¢ãããžã£ãŒã蚪åçè·åž«ãä¿éºè¬å€åž«ãæ£è ã®å®¶æçïŒãšæ å ±ãå ±æããã
4. å°åå»çã«é¢ããå»çã¹ã¿ããã«å¯ŸããŠå ¥é¢æ£è æ å ±ïŒç¹ã«ããååŠçæ³ãæœè¡ãããæ£è ã®å
åŠçæ³åã䜿çšããŠããæããå€åãäž»ãªå¯äœçšïŒãªã©ãæäŸããã
5. èãããçµéŒ»çµç®¡æ é€ãå®æœããŠããæ£è ãéé¢ããå Žåã«ã¯ãå»è¬åã®ééæ§ãé åå€åé²æ¢ç
ã«ãããæ å ±ãæ£è ã家æãåšå® å»çæ åœè ïŒãããã€ãå»ãã±ã¢ãããžã£ãŒã蚪åçè·åž«ãä¿éºè¬
å€åž«çïŒãšå ±æããããšã«ããããã¥ãŒãéå¡ãåé¿ããå¿ èŠãããããããã«ã€ããŠãæ é€ãµããŒ
ãããŒã çãéé¢æãµããªãŒãäœæããéé¢åŸã®åšå® å»çã®æ åœè ã«å¯ŸããŠæžé¢ã§æ å ±æäŸãè¡ãã
ãŸãã耥ç¡æ²»çã«ãããŠã¯ã埮éå çŽ ã®æåãªã©ã«ããæ é€æ¹åã耥ç¡ã®ã¹ããŒãžã»åµé¢ã®æ¹¿æœ€åºŠã«
å¿ããæ²»çè¬ã®éžæã®å¿ èŠã«ã€ããŠæ å ±ãæäŸããŠæ²»çæéãççž®ã«åªããã
6. å€æ¥æ£è ã«ãããŠããè æ©èœäœäžãèããããæ£è æ€æ»ããŒã¿ãæ¥ã æœåºããŠæçšè¬å€ã確èªãã
èµ·å è¬ç©ãæ確ã«ãªã£ãå Žåã«ã¯é©åãªè¬å€ãžã®å€æŽãæžéã»äžæ¢ãå»åž«ã«ææ¡ãããç¹ã«é«éœ¢ã®æ£
è ã§ã¯ãã¢ãã¿ãªã³ã°ã泚ææ·±ãç¶ç¶ããã
7. 粟ç¥çŸæ£æ£è ã¯äž»æ²»å»äº€ä»£ãªã©ã®æ åœå»çã¹ã¿ããã®å€æŽã倧ããªã¹ãã¬ã¹ã«ãªãäºãå°ãªããªãã
è¬å€åž«ãå ¥é¢ããå€æ¥ãŸã§äžè²«ããæ åœå¶ãè¡ã£ãŠããæœèšã§ããã°ãè¬å€åž«ããã®ã¹ãã¬ã¹ã®ç·©è¡
圹ãæãããããšãæåŸ ãããããŸããæ åœå¶ãå®æœäžå¯èœã§ããæœèšã«ãããŠãã䞻治å»äº€ä»£æã®
äžå®æã軜æžããããã«ãæ¥é ããè¬å€åž«ãå ¥é¢æ£è ã°ããã§ãªãå€æ¥æ£è ã«å¯ŸããŠãååãªã³ãã¥
ãã±ãŒã·ã§ã³ãå³ãã€ã€è¬åŠç管çã«åªããã
8. åšå® ã§ã¯ãæè¬ç®¡çã¯æ£è èªèº«ãŸãã¯å®¶æã«å§ããããããæ£è èªèº«ãä»è·å®¶æãé«éœ¢ã®å Žåã
ç解åãäœäžããé©åãªè¬ç©æäžæ¹æ³ãéµå®ãããŠããªãé »åºŠãé«ããªããæ£è èªèº«ãä»è·è ã«å¯Ÿã
ã¢ããã¢ã©ã³ã¹ã®åäžã«åããŠé©åãã€äžå¯§ãªæè¬æå°ãäžå¯æ¬ ã§ããã蚪å蚺çå»åž«ã蚪åçè·åž«
çãšé£æºããªããæè¬èªç«ã«ãããæ¯æŽãæäŸããã
9. å± å® çé€ç®¡çæå°ã蚪åè¬å€ç®¡çæå°ãè¡ã£ãŠããæ£è ã®ç æ ããã³æè¬ç¶æ³ãææ¡ããå»åž«ã
çè·åž«ãä»è·è ã家æçãšãé£æºããŠãå»è¬åã«ããå¯äœçšã®çºçŸç¶æ³ããé£äºã»ææ³ã»ç¡ç ã»éå
çã®æ©èœãžã®åœ±é¿ãå䜵çã䜵çºããå¯èœæ§ãªã©ã«ã€ããŠç¶ç¶ããŠçµé芳å¯ãããADLïŒæ¥åžžç掻å
äœïŒã代è¬ã»ææ³ã»å¥äžçã®äœäžãããã°ãåå ãšãªãè¬å€ãæ€èšããæäžéãå€åã®å€æŽãææ¡ã
8
ãããŸããé©åãªå»è¬åãæè¬è£å©å ·çã®äœ¿çšãææ¡ããè¬ç©çæ³ãé©æ£åããæ£è ã® QOL åäžã«åª
ããã
æ¥åäŸ-â£
è¬ç©ã®è¡äžæ¿åºŠãå¯äœçšã®ã¢ãã¿ãªã³ã°çã«åºã¥ããå¯äœçšã®çºçŸç¶æ³ãæå¹æ§ã®ç¢ºèªãè¡ããš
ãšãã«ãå»åž«ã«å¯Ÿããå¿ èŠã«å¿ããŠè¬å€ã®å€æŽçãææ¡ããããšã
ã解éã
è¬å€åž«ãç¹ã«ç æ£è¬å€åž«ã¯ãè¬ç©çæ³ãè¡ã£ãŠããæ£è ã«ã€ããŠãTDM ããã€ã¿ã«ãµã€ã³ã®ç¢ºèªãã
ãã«å¿ èŠã«å¿ããŠãã£ãžã«ã«ã¢ã»ã¹ã¡ã³ãçã«ãããå¯äœçšãæå¹æ§ã確èªããå¿ èŠã«å¿ããŠæé©ãª
è¬å€ãšãã®æäžéãæäžæéãç®åºããè¬å€ã®å€æŽçãå«ããæé©ãªè¬ç©çæ³ã®åŠæ¹ãç©æ¥µçã«ææ¡
ããã
ã解éã®å ·äœäŸã
1. è æ©èœãäœäžããŠããæ£è ã§ã¯ãè¬ç©ã®è èããã®ææ³é 延ããããã«äŒŽãè¬ç©ã®äœå èç©ã«ãã
å¯äœçšçºçŸãäžæ¯ãåŒãèµ·ãããããªãã®ã§ãè¬å€åž«ãç¶ç¶ã㊠TDM ãå®æœããŠããã®çµæã解æãã
é©åãªæäžéãå»åž«ã«ææ¡ããã
2. æ²»çå®å šåã®çãè¬å€ãæçšããŠããæ£è ã«ã€ããŠã¯ãçžäºäœçšã«ããè¬å€ã®è¡äžæ¿åºŠã®å€åãè
æ ®ããTDM ã®ããŒã¿ãåºã«å¯äœçšã®çºçŸç¶æ³ïŒãã€ã¿ã«ãµã€ã³ãç®èã®ãã§ãã¯ã«ããïŒãæå¹æ§ã®ç¢º
èªãè¡ããšãšãã«ãå»åž«ã«å¯ŸããŠãæ€æ»ãªãŒããè¬å€ãè¬å€éã®å€æŽçãææ¡ããã
3. æããè¬ãæèè¬ãé 圱å€ãè¡æ¶²è£œå€çã®æ³šå°å€ãæäžããéãç æ£è¬å€åž«ã¯ãæäžåã«æ£è ã®ç¶
æ ãååã«ææ¡ããæäžäžããæäžåŸãããããµã€ããã©ãŠã³ãããŠãæ¯èŠãããåãæ°ãåæžçã®
èªèŠçç¶ã®å€åãæèã®æ··æ¿ããããã¿çã®ã¢ããã£ã©ãã·ãŒã·ã§ãã¯çç¶ãçµé芳å¯ããå¿ èŠã«å¿
ããŠå»åž«ãžé£çµ¡ããè¬å€æäžã®äžæ¢ãç·æ¥å¯Ÿå¿è¬ãææ¡ããã
4. ã€ãªããã«ã³ãçšããããè¬ç©çæ³ãè¡ãéã«ãäºåã«äœæããããããã³ãŒã«ã«åºã¥ããŠæ£è ãž
ã® UGT1A1 éºäŒåå€å解æã®èª¬æã»åæãååŸãããããã³ãŒã«ã«åŸã£ãŠæ€æ»ãªãŒããè¡ããåŸããã
çµæãåºã«ãå¿ èŠã«å¿ãã€ãªããã«ã³ã®æäžéããä»ã®ã¬ãžã¡ã³ãžã®å€æŽã«ã€ããŠå»åž«ãšåè°ããã
ããå®å šãªããè¬ç©çæ³ã®å®æœã«åªããã
5. é質æ§èºççã®çºçŸé »åºŠã®é«ãè¬å€ïŒã²ãã£ãããçã®ææªæ§è «çè¬ïŒãæäžããŠããæ£è ã«å¯Ÿã
ãŠã空å³ãæ¯åããçºç±ãåŒåžå°é£çã®èªèŠçç¶ã®ç¢ºèªãèŽèšºã«ããæ»é«ªé³çãã£ãžã«ã«ã¢ã»ã¹ã¡ã³
9
ããé質æ§èºççã®è¡æž ããŒã«ãŒã§ãã CRPãLDHãKL-6 ãªã©è¡æ¶²æ€æ»å€çãçµé芳å¯ããé質æ§èºç
ã®æ©æçºèŠã«åªããé©åãªå¯Ÿå¿ãææ¡ããã
6. ååæšçè¬çã®æ°èŠè¬ç©æ²»çã«ã€ããŠã¯å€æ¥æ£è ã®ç¶ç¶çå¯äœçšã¢ãã¿ãªã³ã°ã¯éèŠã§ãããè¬å€
åž«å€æ¥çãèšçœ®ããæ足çå矀ïŒHFSïŒã®ã¢ãã¿ãªã³ã°ããããã¯ãããããç¯å²å ã§ã®å€çšè¬ã®éžæ
ãšäœ¿çšã«é¢äžããã
7. TDM ãå®æœãã¹ãè¬ç©ãæäžãããŠããå Žåã«ã¯ãæ€æ»ãªãŒãã管çããããã³ãŒã«ãéµå®ããã
ãŸãããã®çµæãè©äŸ¡ãããšå ±ã«ãè¬ç©ã®èšåºå¹æãå¯äœçšã«ã€ããŠãè©äŸ¡ãæäžèšç»ãç«æ¡ããã
ãŸã代è¬ç°åžžãåŒãèµ·ããå¯èœæ§ã®ããè¬ç©ãæäžãããŠããå Žåã«ã¯ãè¡æ¶²æ€æ»ã BMI çã®ã¢ãã¿
ãªã³ã°ãè¡ããå»åž«ã«é©åãªåŠæ¹ææ¡ãè¡ãã
8. æ粟ç¥ç è¬æäžã«äŒŽãéäœå€è·¯çç¶ã«ã€ããŠãè¬åæ§éäœå€è·¯çç¶è©äŸ¡å°ºåºŠïŒDIEPSSïŒãçšããŠè©
䟡ããå¿ èŠã«å¿ããŠæäžéã®æžéã»äžæ¢ãããã¯è¬å€ã®å€æŽçã®åŠæ¹å€æŽãææ¡ããã䜵ããŠãäžé©
åãªæè¬äžæãªã©ã«ããéäœå€è·¯çç¶ãåŒãèµ·ããããªãããæ£è ã«èª¬æããæ£è ãæ²»çãç¶ç¶ãã
ããããå€åœ¢ãçšæ³çãå«ããŠå»åž«ã«ææ¡ããã
9. ã©ã¢ããªã®ã³ã®äœ¿çšã«éããŠã¯ãç®èçç¶çã®å¯äœçšçºçŸãåé¿ããããã䜵çšè¬ã®æç¡ã»çš®é¡ã»
代è¬çµè·¯ãåå確èªããé©åãªæäžéãå¢éæ¹æ³ãå»åž«ã«ææ¡ãããè¬ç¹ã®çºèŠãé ãéçåããã±
ãŒã¹ããããããæ©æçºèŠã«åªããã
10. ã¯ã«ãã¡ãªã³ãªã©ãæçšããŠããæ£è ã«ã€ããŠã¯ãçžäºäœçšã«ããè¬å€ã®è¡äžæ¿åºŠäžæãè¡æ¶²å
åºèœã瀺ã PT-INR ã®å»¶é·ãªã©ãèæ ®ããTDM ãååºç³»æ€æ»ã®å®æœãå»åž«ãžææ¡ããããŸããæ£è ãžã®
説æãçŽæ¥èŠ³å¯ãæ€æ»ããŒã¿ãç¶ç¶çã«ã¢ãã¿ãŒããå¯äœçšã®æ©æçºèŠã«åªããã
æ¥åäŸ-â€
è¬ç©æ²»çã®çµéçã確èªããäžã§ãå»åž«ã«å¯Ÿããååã®åŠæ¹å 容ãšåäžã®å 容ã®åŠæ¹ãææ¡ãã
ããšã
ã解éã
çç¶ãå®å®ããŠããæ£è ã«ã€ããŠã¯ãäºåã®å»åž«ãšã®åæã«åºã¥ããå¯äœçšçç¶ã®æç¡ãèšåºæ€æ»
å€çã®æ£è æ å ±ãèšé²ããè¬æŽçã確èªããåé¡ããªãå Žåã«ã¯ãããŸã§ã®åŠæ¹ãç¶ç¶ããããå»åž«
ã«ææ¡ãããæ£è ç¶æ ã«åé¡ãèŠã€ããå Žåã«ã¯ãã®åé¡ç¹ãå»åž«ã«é£çµ¡ããŠãåŠæ¹è¬ã®å€åœ¢å€æŽ
ïŒæ£å€ã»é å€ïŒãäžå å調å€ãæäžæ¥æ°ã®èª¿æŽçãææ¡ããã
10
ã解éã®å ·äœäŸã
1. å æã»å€çšè¬ã®å®æç¶ç¶åŠæ¹ã«ã€ããŠãæ£è ç¶æ ã«å€ããããªããã°å»åž«ãšäºååæãåŸãŠãç¶ç¶
è¬ã®åŠæ¹ææ¡ãè¡ãã
2. è¬å€äº€ä»çªå£ã«ãŠæè¬æå°ãè¡ã£ãçµæãäžå åãäžå åäžèŠçã®èŠæããã£ãå Žåã¯ãå»çæ å ±
ã·ã¹ãã ãå©çšãããªã©ããŠäž»æ²»å»ã«äŒéããé©åã«å¯Ÿå¿ããã
3. æ ¢æ§éªšé«æ§çœè¡ç æ£è ã骚é«è «ã®å€æ¥æ£è ã«å¯ŸããŠãååæå°æã®ã€ã³ã¿ãã¥ãŒããã³åæ¥æã®ã
ã©ããŒã¢ããã«åºã¥ããã¢ããã¢ã©ã³ã¹ã®ç¢ºä¿ã«åªããããŸããå¯äœçšãããžã¡ã³ãã«å¿ èŠãªåŠæ¹æ
æ¡ãè¡ãã
æ¥åäŸ-â¥
å€æ¥ååŠçæ³ãåããŠããæ£è ã«å¯Ÿããå»åž«çãšååããŠã€ã³ãã©ãŒã ãã³ã³ã»ã³ããå®æœãã
ãšãšãã«ãè¬åŠç管çãè¡ãããšã
ã解éã
ããæ²»çã«ãããŠãå€æ¥ååŠçæ³ãæ¥æ¿ã«å¢å ããŠãããååŠçæ³è¬å€ã®æ§ã ãªçµã¿åããã«ãã
å€ãã®ã¬ãžã¡ã³ãææ¡ãããæ²»çã«çšããããŠããããŸããå€æ§ãªäœçšæ©æ§ãæã€ååæšçè¬ãæäœ
è¬ãéçºãããå€ãã®ã¬ãžã¡ã³ã§äœ¿çšãããŠãããæ£è äžå¿ã®ããŒã å»çã«ãããŠãååã«å»çåŸäº
è ãšæ£è ã家æã®éã§ã³ãã¥ãã±ãŒã·ã§ã³ãåããŠããããšãæ²»çã®æåã®ããã«éèŠã§ãããè¬å€
åž«ã«å¯ŸããæåŸ ã倧ãããå€æ¥ååŠçæ³ã®æåã«ã¯ãå¯äœçšã®ã³ã³ãããŒã«ãé節åã®é²æ¢ãéèŠã§
ããã
å€æ¥ååŠçæ³ãåããæ£è ã«å¯ŸããŠãå»åž«ã«ããæ²»çæ¹éçã®èª¬æåŸã«ãè¬å€åž«ãæããè¬ã«ãã
æ²»çã¹ã±ãžã¥ãŒã«ãæå¹æ§ãå¯äœçšçã詳现ã«èª¬æããå¯äœçšã®è»œæžã®ããã®å¯Ÿå¿æ¹æ³ãšçºçŸã®èšé²
ã«åºã¥ããŠã€ã³ãã©ãŒã ãã³ã³ã»ã³ããå®æœããããŸããæããå€ãæäžããŠããéã«æ£è ç¶æ³ãã©
ãŠã³ãããŠæ£è ç¶æ³ãææ¡ããæããè¬æäžã§åºçŸããé 延æ§å¯äœçšãå«ãå¯äœçšã®ææ¡ããããã«
察å¿ããé©åãªæ¯æçæ³ã®ææ¡ãæ£è ã®çžè«ã«å¿ãããªã©ãæ£è ã®èŠçãäžå®ã軜æžããããã®å¯Ÿç
ãè¡ãã
ã解éã®å ·äœäŸã
1. ããååŠçæ³ã«çšããè¬å€ãååæšçè¬ã®äœçšãå¯äœçšãå¯äœçšã®å¯Ÿççã«ã€ããŠã¯ãååæã«ã
ãã³ãã¬ããçãçšããŠå¹³æãªèšèã§æ£è ã«èª¬æããè¬ç©çæ³ã«ã€ããŠååã«ç解ããŠæ²»çã«ç©æ¥µç
ã«åå ã§ããããã«æ¯æŽããã2åç®ä»¥éã¯ãååã®ååŠçæ³ã®å¯äœçšçã確èªããå¿ èŠã«å¿ããŠãé©
11
åãªçŒçç·©åãå«ããæ¯æçæ³ãå»åž«ã«ææ¡ãããã
2. å€æ¥ååŠçæ³å®€ã«è¬å€åž«ãåžžé§ããäœå¶ãã€ãããããååŠçæ³ã«ããå¯äœçšçç¶ããã§ãã¯ãã
å¯äœçšã®è»œæžãããã¯åé¿ã®ããã®åŠæ¹ãææ¡ããã
3. ååŠçæ³ã«ãããŠãå¶åå€ã»åœè¬ã»ä¿æ¹¿å€çã®åŠæ¹ã確èªããäžè¶³ããŠããå Žåã¯åŠæ¹ææ¡ãè¡ãã
4. ååŠçæ³æœè¡æ£è ã«å¯ŸããååŠçæ³æœè¡äžã«ã©ãŠã³ããè¡ãå¯äœçšã»æ³šæäºé ç説æãå®æœããã
ãŸããåž°å® åŸã«èµ·ããå¯èœæ§ã®ããé 延æ§å¯äœçšã®çç¶ãçºçæã®å¯Ÿå¿çãæ£è ã«èª¬æãããšãšãã«ã
çžè«ã«å¿ããã
æ¥åäŸ-âŠ
å ¥é¢æ£è ã®æåè¬ã®å 容ã確èªããäžã§ãå»åž«ã«å¯Ÿããæè¬èšç»ãææ¡ããçãåœè©²æ£è ã«å¯Ÿã
ãè¬åŠç管çãè¡ãããšã
ã解éã
æ£è ã¯è€æ°ã®å»çæ©é¢ãå蚺ããŠããããšãå€ããè€æ°ã®é¡äŒŒè¬ãçžäºäœçšã«æ³šæãã¹ãè¬å€ãã
ãã¯äœµçšçŠå¿ã®è¬å€ããçžäºäœçšã䜵çšçŠå¿ã®é£åïŒç¹å®ä¿å¥çšé£åãå«ãïŒãæåããŠããããšã
å€ããè¬å€åž«ã¯ãå ¥é¢æ£è ã®æåè¬ã®éå¥ã«ãšã©ãŸãããç åãšãã®åŠ¥åœæ§ã確èªãããšãšãã«ãä¿
管管çã代æ¿è¬ã®ææ¡ãåŠæ¹è¬ãšã®çžäºäœçšãéè€æäžã䜵çšçŠå¿çã®åé¿ã«åªããªããã°ãªããªãã
å ¥é¢äžã®é©æ£ãªè¬å€ã®éžæãšæè¡ã»æ€æ»ã®æ¥çšã«åãããåŠæ¹ææ¡ãè¡ããããã«ãæ£è ã«å¯ŸããŠã
ããå»è¬åæäžã«é¢é£ããè¬åŠç管çãè¡ãã
ã解éã®å ·äœäŸã
1. æ£è ç¶æ³ãæåè¬æ å ±ãšåé¡ç¹ïŒã³ã³ãã©ã€ã¢ã³ã¹ãçžäºäœçšãéè€ãæè¡ã»æ€æ»ã«åœ±é¿ããè¬å€ã
çŠå¿çã®è¬åŠçèå¯ãééæè¬ã«ããèªæ®ºäŒå³ïŒãæ€èšããŠãå»åž«ãšåè°ããã
2. æåè¬ã®è¬å€ã»æäžéãé©åãã確èªããäžé©åãªå Žåã«ã¯é©æ£ãªè¬å€ã»æäžéãªã©ã®åŠæ¹ææ¡ã
è¡ããæåè¬ãç¶ç¶äœ¿çšããå Žåãé¡äŒŒåã®æ¡çšè¬ãããå Žåã«ã¯ãåŠæ¹èª€å ¥åã®é²æ¢ã«åªããã
ïŒå»è¬åå»çæ©åšçå®å šæ§æ å ± ïœïŒïŒïŒïŒ
3. å ¥é¢äºçŽæã«æåè¬ç®¡çã»ã³ã¿ãŒçã§æçšäžã®è¬å€ãç¹å®ä¿å¥çšé£åãªã©ãå ¥ããè¬è¢ãæ£è ã«æ
æž¡ããå ¥é¢ããéã«æ£è ãšé¢è«ããæçšè¬å€ãæçšæ¹æ³ããã³æçšéã確èªããããŸããé»åã«ã«ã
äžã«æåè¬æ å ±ãšåé¡ç¹ãå ¥åããå ¥é¢äžã®åŠæ¹ãææ¡ããã
12
4. ä»è·è人ä¿å¥æœèšïŒèå¥ïŒã»ä»è·è人çŠç¥æœèšçã®å ¥æè ã«ãããŠããæ£è ç¶æ³ã«ã€ããŠä»è·æ åœ
è çãšåè°ããé©åãªè¬ç©æ²»çãç¶ç¶ã§ãããããµããŒãããã
æ¥åäŸ-â§
å®æçã«æ£è ã®å¯äœçšã®çºçŸç¶æ³ã®ç¢ºèªçãè¡ããããåŠæ¹å 容ãåå²ããŠèª¿å€ããããšã
ã解éã
æ¯èŒççç¶ãå®å®ããŠãããé·ææäžãåããŠããæ£è ã®å€æ¥åŠæ¹ããã«ã€ããŠã¯ãäŸãã°ãå®æ
çïŒäžã¶ææ¯ïŒãªæ£è ã®è¬å±ãžã®æ¥èšªãè¥ããã¯è¬å€åž«ã®å± å® çãžã®èšªåã«ãããé·æåŠæ¹ãåå²ã
ãŠèª¿å€ãè¡ããè¬å€åž«ã¯ããã®éœåºŠãæ£è ã®èªèŠçç¶ããã€ã¿ã«ãµã€ã³ã®ç¢ºèªãããã«ã家æããã®
æ å ±åéçã«ãããå¯äœçšãæ²»çå¹æãªã©ã®è©äŸ¡ãè¡ããæ²»çã®ç¶ç¶ã®åŠ¥åœæ§ãå€æãããšãšãã«ã
ãã®ç¶æ³çã«ã€ããŠãæ£è ãžã®èª¬æãè¡ããããã«ãå¿ èŠã«å¿ããŠåŠæ¹å»ãžã®åŠæ¹ææ¡ãè¡ãããŸãã
è©äŸ¡ã®çµæãæ£è ã®ç¶æ ã«åé¡ãçããŠãããšå€æããå Žåçã«ã¯ãåŠæ¹ãããçºè¡ããå»åž«ãžã®å
蚺å§å¥šãè¡ããšãšãã«ãé æ»ãªãå»åž«ã«ãé£çµ¡ããã
æ¥åäŸ-âš
æããå€çã®é©åãªç¡è調補ãè¡ãããšã
ã解éã
National Institute of Occupational Safety and Health (NIOSH)ãã 2004 幎ã«èŠåãå»çç°å¢ã«
ãããŠæããè¬ãä»ã®å±éºãªå»è¬åã«å»çåŸäºè ã被æããªãããã«ããåºãããŠä»¥æ¥ãæããè¬ã®
ç¡è調補ãå®å šã«è¡ããå»çåŸäºè ã®å®å šã確ä¿ããããšãæ±ããããããã«ãªã£ãããã®ããã«ã¯ã
ãã¬ãŒãã³ã°ãåããè¬å€åž«ããæããè¬ãåãæ±ãå šãŠã®å»çæ©é¢ã§ãå šãŠã®æ£è ã«å¯ŸããŠééç³»
ã®é£æ£é²æ¢åšå ·ãçšããŠãå®å šãã£ããããã®äžã§ç¡èçã«è¡ãããšãå¿ èŠã§ãããããã«ãçè·åž«
ãšååããŠã調補ããæããè¬å€ã®æäžåã®ã»ããã³ã°ãæäžã«ãŒãã®ç¢ºä¿ãæäžé床ã®èšå®çãè¡
ããè¬å€åž«ã«ããæããè¬ã®ç¡è調補ã«ã€ããŠã¯ãå šåœã®ããååŠçæ³ãå®æœããŠããç é¢ã® 77ïŒ ã§
å®æœãããŠããïŒå¹³æ 25幎床ãæ¥ç è¬ã«ããç é¢è¬å€éšéã®çŸç¶èª¿æ»ãïŒã
ïŒïŒè¬å€ã«é¢ããçžè«äœå¶ã®æŽå
13
è¬å€åž«ä»¥å€ã®å»çã¹ã¿ããããããããã®å°éæ§ã掻ãããŠè¬å€ã«é¢ããæ¥åãè¡ãå Žåã«ãã
ãŠããå»çå®å šã®ç¢ºä¿ã«äžå šãæã芳ç¹ãããè¬å€åž«ã®å©èšãå¿ èŠãšããå Žé¢ãæ³å®ãããããš
ãããè¬å€ã®å°é家ãšããŠåå»çã¹ã¿ããããã®çžè«ã«å¿ããããšãã§ããäœå¶ãæŽããããšã
æãŸããã
ã解éã
è¬å€åž«ã¯ãè¬ã®ãããã§ãã·ã§ãã«ãšããŠå»è¬åãšè¬ç©çæ³ã«è²¬ä»»ãæã€ããšãå¿ èŠã§ããããŸãã
è¿å¹Žãå»è¬åã¯ååæšçè¬ãªã©ã®ããã«é«åºŠåã»å€æ§åãããã®äœ¿çšæ¹æ³ã察象æ£è ãé©å¿çãªã©ã®
å€æãé£ãããªã£ãŠããããŸããæ£è ã®ç¶æ³ã«å¿ããŠãå»åž«ãçè·åž«ããè¬ç©çæ³ã«é¢ãã質åãå€
æ§åãã€ç·æ¥åããŠãããåŸã£ãŠãè¬å€åž«ã¯å€æ§ãªå»è¬åãšé©å¿çŸæ£ãç æ ãç çã«ç²ŸéããŠããã¹
ãã§ãããè¬å€åž«ã¯ãå»çããŒã ã®äžå¡ãšããŠãæ£è ã®å®å šé¢ãç¹ã«è¬å€ã®æå¹æ§ã»å®å šæ§ãªã©ã«è²¬
ä»»ãè² ãã®ã§ãç æ£ã«è¬å€åž«ãåžžé§ããŠæ¥åãè¡ãäœå¶ãæ©æ¥ã«æ§ç¯ãããšãšãã«ãçš®ã ã®çåãžã®
察å¿ãé©åãªå©èšãããããã®å»è¬åæ å ±éšéã匷åã»æŽåããå¿ èŠãããã
ç¹ã«ãå°å ç§é åã粟ç¥ç§é åã«ãããŠã¯ãæ£è ã®ã¿ãªããã家æã«å¯ŸããŠãåå¥ã«è¬ç©çæ³ã«é¢
ããæ å ±æäŸãçžè«æ¥åãè¡ãããšã«ãããè¬ç©çæ³ã«å¯Ÿããçåãäžå®ã解æ¶ããç解ãæ·±ããã
ãšãã§ããã
14
â ¢. å®è·µäºäŸ
ïŒæ¥åäŸ-â ïŒïŒïŒ®ïŒ³ïŒŽïŒ
ããŒã å åšè¡ææ é€ç®¡çïœå€æ¥ããå ¥é¢ã»éé¢ãžïœå°åé£æºå NST
ããŒã ã圢æããç®ç
å€è·çš®ã§å€æ¥ãã NST ã«ããæ é€ä»å ¥ãå®æœããããšã§è¡åŸå䜵ççºççã®
æžå°ãè¡åŸåšé¢æ¥æ°ã®ççž®ãããã«ã¯è»¢åž°ã®æ¹åãç®æãïŒNST ã¯å€æ¥ããïŒã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬å€åž«ã¯è¬ç©çæ³ã«ãããææ¡ãççŸ©ç §äŒæã«ãåæã«åºã¥ãããããã³ãŒã«
ã«åºã¥ãåŠæ¹ã»æ³šå°ã»æ€æ»ããªãŒãããçãæ£è æ¯æŽãå»çã¹ã¿ããã®æ¥åè²
æ 軜æžãè¡ããïŒæ¥æ¬éèçµè žæ é€åŠäŒ æ é€ãµããŒãããŒã å°éçæ³å£«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ å䜵ççºçæ°ããã¬ã¢ã«ããã³ïŒTTRïŒ ã«ã€ããŠå®èšŒäºæ¥ååŸã§ã®æ¯èŒæ€èš
ããã»ã¹è©äŸ¡ å ç«è£å©æ é€å€å®æœç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è¡åŸå䜵ççºçç
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åšé¢æ¥æ°
ããã»ã¹è©äŸ¡ æ²»çå 容ã®ç解ãå«ããæ£è æå°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è¡åŸåšé¢æ¥æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«çè·åž«ãžã®ã¢ã³ã±ãŒã調æ»
ããã»ã¹è©äŸ¡ ã¢ã³ã±ãŒãçµæ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è¬å€åž«ç æ£é 眮
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ å ç«æ é€è£å©å€éé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é£äºçæ³ã®ç解ãã»ã«ãã¢ãã¿ãªã³ã°ã®å®è¡ãéé¢åŸã®é£äºçæ³
å ·äœçãªææã»å¹æ
1) è¡åæ é€ä»å ¥åŸã®è¡åŸå䜵ççºçç㯠37.8ïŒ ãšå€åãèªããªãã£ããTTR
ã¯å€æ¥æã®å¹³åã 17.6mg/dlãå ¥é¢æã 18.3 mg/dl ãšäžæåŸåã瀺ããã
å€æ¥ã§ SGA ã«ãŠè©äŸ¡ãå ¥é¢ãŸã§ã« NST ãä»å ¥ããããšã§è¡åŸå䜵çã®æž
å°ãè¡åŸåšé¢æ¥æ°ã®ççž®ãªã©ãåŸããå»çã®è³ªåäžã«ã€ãªãããšèããã
ãã
2) è¡åæ é€ä»å ¥åŸã®è¡åŸåšé¢æ¥æ°äžå€®å€ã¯ 13.5 æ¥ã§ãä»å ¥åã® 17.5 æ¥ãšæ¯
èŒããŠææã«ççž®ããã
3) æ£è ããã®è»¢åž°ã®æ¹åã«ããæ é€ã«å¯ŸããæèãåäžããåŽåçç£æ§ãæ¹
åãçžå¯Ÿçã«äººçã³ã¹ããåæžãããå¯èœæ§ãããã
4) åšè¡æã®æ é€ç®¡çã«é¢ããŠã¯ãå€è·çš®ãåŸæåéã§ã®æ¥åãèžè¥²ããããš
ã§æåŸ éãã® çµæãåŸãããšãã§ããã
ææçãçºè¡šããåŠäŒ 1) 䞞山垞圊ã»ã, æ¶å管çã«å¯Ÿããã·ãŒã ã¬ã¹ãªæ é€ç®¡ç. 第 8 åæ¥æ¬æ¶å
管åŠäŒç·äŒåŠè¡éäŒ (2012)
15
ïŒæ¥åäŸ-â ïŒïŒïŒšïŒ©ïŒ¶ïŒ
ããŒã å HIV 蚺çããŒã
ããŒã ã圢æããç®ç
åå°éè·ã®å¹ççãªæ¥ååæ ãšç·å¯ãªé£æºã«ãããæ£è ãžã®ç·åçãã€è¯
質ãå°éçãªå»çæäŸãç®çãšããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æ²»çéå§åããç¶ç¶æã«ãããæ£è ãžã®æè¬æ¯æŽãæ£è èæ¯ãèæ ®ããåŠæ¹
èšèšãTDM ã«ããè¬ç©çžäºäœçšã»è¬ç©äœå åæ ã®è©äŸ¡ãå»è¬åæ å ±ã®åéã»
æäŸ (æ¥æ¬ç é¢è¬å€åž«äŒ HIV ææçå°éè¬å€åž«)
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ãšã€ãºé¢é£çŸæ£ã«ããæ»äº¡çããšã€ãºé¢é£çŸæ£ã«ããå ¥é¢çããšã€ãºçºççã
HIV-RNA éãCD4 æ°
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããæ HIV çæ³éå§åã®é¢è«å®æœçãæ HIV è¬ã®æè¬éµå®ç(ã¢
ããã¢ã©ã³ã¹)
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ HIV ææçå°éè¬å€åž«ã»HIV ææçè¬ç©çæ³èªå®è¬å€åž«ã®é 眮ãå®æçãª
ããŒã ã«ã³ãã¡ã¬ã³ã¹ã®éå¬
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ HIV-RNA éãCD4 æ°ãæè¬ã¢ããã¢ã©ã³ã¹ãQOL
ããã»ã¹è©äŸ¡ HIV ææçå°éè¬å€åž«ã»HIV ææçè¬ç©çæ³èªå®è¬å€åž«ã«ããæè¬æå°ã®
å®æœãæ£è ã®æ HIV çæ³ã«å¯Ÿããç解床
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ HIV ææçå°éè¬å€åž«ã»HIV ææçè¬ç©çæ³èªå®è¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«ã«ããæ£è ãžã®æ HIV çæ³ã«é¢ãã説ææéãåå°éè·çš®ã®å°éæ§ã
å»è¬åæ å ±åéã®å¹çå
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããæè¬æå°ã®å®æœåæ°ããã³å®æœæéãããŒã ã«ã³ãã¡ã¬ã³ã¹ã®
éå¬ç¶æ³ãä»è·çš®ãšã®çžè«åæ°ããã³çžè«æé
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å®æçãªããŒã ã«ã³ãã¡ã¬ã³ã¹ã®éå¬ãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ ãŠã€ã«ã¹çŸæ£æå°æ 2ãããŒã å»çå ç®ç®å®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ HIV 蚺çã«åŸäºããå°ä»»å»åž«ãå°ä»»è¬å€åž«ãå°åŸçè·åž«ã瀟äŒçŠç¥å£«ã粟
ç¥ä¿å¥çŠç¥å£«ã®é 眮ããã©ã€ãã·ãŒä¿è·ã«é æ ®ããçžè«å®€ã»èšºå¯å®€ã®èšçœ®
å ·äœçãªææã»å¹æ
è¬å€åž«ã«ããæ HIV çæ³ã®åŠæ¹ã¡ãã¥ãŒã®ææ¡ã®ãã¡ã95.6%ãå»åž«ã«æ¡
æãããæ²»çéå§åŸ 48 é±æç¹ã®ãŠã€ã«ã¹æå¶ç㯠91.7%(ITT 解æ)ã§ã
ã£ãã
ææçãçºè¡šããåŠäŒ
1) åæ¬éä»ã»ã, HIV ææçæ²»çãžã®è¬å€åž«ã®é¢ãã. 第 18 åæ¥æ¬å»ç
è¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 340 (2008)
2) åæ¬éä»ã»ã, HIV ææçæ²»çã«ãããè¬å€åž«ä»å ¥äºäŸã®è§£æãšãã®
è©äŸ¡. 第ïŒïŒåæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 394 (2013)
ææçãå ±åããè«æã»éèª
1) Kunimoto Y et al., Coadministration of tenofovir decreased ataza-
navir plasma concentration after unilateral nephrectomy. J
Infection Chemother 19(4): 750-753 (2013)
2) åæ¬éä»ã»ã, ãã®çŸæ£ã§ã¯ã©ããã!? æ€æ»ã®å®éãšããããã©ãŒã«
HIV. è¬å± 65(2): 109-114 (2014)
16
ïŒæ¥åäŸ-â¡ïŒïŒããïŒ
ããŒã å ååŠçæ³ã¬ãžã¡ã³çµ±äžããŒã
ããŒã ã圢æããç®ç
ããååŠçæ³ã®å¶åçæ³ã®é©æ£åãæšæºåãšå®å šç®¡çã®ããã®é¢å éçšã«ã€ã
ãŠæ€èšããé¢å ã¬ã€ãã©ã€ã³ãçå®ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
ããååŠçæ³ã®å®å šç®¡çãéçšäžã®åé¡ç¹ãèŠæãªã©ã«ã€ããŠãç¹ã«è¬å€ã®é©
æ£äœ¿çšãå®å šç®¡çãè¬å€èª¿è£œãšæãåºããªã©ãè¬å€åž«ã®ç«å Žããæ€èšãããé¢
å ã¬ã€ãã©ã€ã³ã®çŽ æ¡ãäœæãããïŒæ¥æ¬ç é¢è¬å€åž«äŒ ããå°éè¬å€åž«ãæ¥æ¬
å»çè¬åŠäŒ ããæå°è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æšæºåã«ããå¶åçæ³ããã³å®å šæ§ã®åäžãæ¥åã®å¹çå
ããã»ã¹è©äŸ¡ åŠæ¹ã®æšæºåã«ããå¶åçæ³ã®åäžãã€ã³ã·ãã³ãçºç件æ°ãè¬å€ç®¡çã®å¹ç
åãè¬å€è²»
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é¢å ã¬ã€ãã©ã€ã³ã®çå®ãšéµå®ãå°éå»ã»å°éè¬å€åž«ã»èªå®çè·åž«ã®é 眮
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ 確å®ãªæªå¿ååäºé²ãšè¬å€è²»è² æ é¡
ããã»ã¹è©äŸ¡ æªå¿ååã®ç¶æ³ãè¬å€è²»è² æ é¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°éå»ãå°éè¬å€åž«ãèªå®çè·åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å¶åçæ³ã®æšæºåãæ¥åã®å¹çå
ããã»ã¹è©äŸ¡ ççŸ©ç §äŒåæ°ãè¬å€ç®¡çã®å¹çåãã€ã³ã·ãã³ãçºç件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é¢å ã¬ã€ãã©ã€ã³ã®çå®ãšéµå®
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¬å€è²»
ããã»ã¹è©äŸ¡ å¶åå€äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é¢å ã¬ã€ãã©ã€ã³ã®çå®ãšéµå®
å ·äœçãªææã»å¹æ 1) ä¹³ããã®è¡åãŸãã¯è¡åŸè£å©ååŠçæ³ãšããŠãã»ã¿ãã»ã«(DTX)åç¬çæ³
ãåããæ£è 97 åã察象ã«èª¿æ»ãå¶åçæ³ãããªã³ãã³ã»ããã³
(OND)4mg ãšãªã³é žãããµã¡ã¿ãœã³(DEX)8 mg ã®äœµçšãã DEX12mg å
ç¬ãžãšå€æŽããè²»çšæå°ååæãè¡ã£ãããªããåæ害äºè±¡ã®çºçŸé »åºŠã§ã¯
ææå·®ã¯èªããããªãã£ãïŒæªå¿ïŒ19.5% vs 16.1%ãp = 0.660ãååïŒ
2.4% vs0%ãp = 0. 423ã䟿ç§ïŒ34.1% vs30.4%ãp = 0. 756ïŒãäžç ïŒ
17.1%vs17.9%ãp = 0.920ïŒã
2) äœå¬åãªã¹ã¯ã®ååŠçæ³ïŒã³ãŒã¹ãããã®è¬å€è²»ã¯ 5,895 ååæžãããã
äžæ¹ãå¶åçæ³ã®å€æŽã«èŠãã人件費㯠41,955 åã§ãã£ããå¶åçæ³ã®å€
æŽã«ãããå°å ¥åŸ 1 幎éã®äœå¬åãªã¹ã¯ååŠçæ³ã«ãããã³ã¹ãåæžå¹æ
ã¯çŽ 800 äžåã§ãã£ããäœå¬åãªã¹ã¯ã®ååŠçæ³ã«ãããå¶åçæ³ãšããŠã
DEX åç¬çæ³ã¯ãæ£è ã±ã¢ã®è³ªãäœäžãããããšãªãã³ã¹ãåæžã«ã€ãªã
ãããšã瀺åãããã
ææçãçºè¡šããåŠäŒ 1) æ çšå±ã»ã,äœå¬åãªã¹ã¯ã®ååŠçæ³ã«å¯Ÿããå¶åçæ³ã®é¢å çµ±äžã«ãã
ãèšåºå¹æã®æ€èšŒãšçµæžè©äŸ¡. 第 20 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé,
413 (2010)
ææçãå ±åããè«æã»éèª 1) Hayashi T et al., Implementation of institutional antiemetic guidelines
for low emetic risk chemotherapy with docetaxel: a clinical and cost
evaluation. Supportive Care in Cancer 20(8): 1805-1810 (2012)
17
ïŒæ¥åäŸ-â¡ïŒïŒããïŒ
ããŒã å è¡æ¶²ããå¶å察çããŒã
ããŒã ã圢æããç®ç
é è¡åšè «çã«å¯ŸããååŠçæ³ã«ãããŠãçžäºäœçšãåŠå®ã§ããªãã¢ãã¬ãã¿ã³
ãããåå°éè·ã®é£æºã«ããå®å šãã€å¹æçã«äœ¿çšããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æ£è æè¬ããã³ååŠçæ³å€ã粟æ»ããå¶åå€ã«é¢ããæç®æ å ±ãå ã«ãã¬ãžã¡
ã³æ¯ã«å¶åçæ³ãå»åž«ã«ææ¡ãæ£è ã«å¯Ÿããæè¬æå°ãå®æœãæ²»çéå§åŸã¯æ£
è ã®æçšè¬ã粟æ»ããåŠæ¹å€æŽã®å¿ èŠæ§ãå»åž«ãšåè°ãïŒæ¥æ¬å»çè¬åŠäŒ ãã
å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ååå¶åŸ¡çã®åäžãå¶åè¬è¿œå ã«ããå¯äœçšã®çºççã移æ€å¹¹çŽ°èã®ççæèŠ
æéã移æ€å䜵çã移æ€åŸçåç
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããæããè¬æäžåã®æè¬æå°ã®å®æœçãå¶åå€ã®æè¬éµå®ç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããå°éè¬å€åž«ã®é 眮ãè¬åæ å ±å®€ãšã®é£æºåŒ·å
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ååå¶åŸ¡çãé£äºæåéãæ²»çç¶ç¶ç
ããã»ã¹è©äŸ¡ ããå°éè¬å€åž«ã«ããæè¬æå°å®æœãçè·åž«ã«ããé©åãªå¯äœçšã¢ãã¿ãªã³ã°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããå°éè¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«ã«ããåŠæ¹æ€èšæéãååŠçæ³ã«é¢ãã説ææéãå»è¬åæ å ±åéã®å¹ç
åãåŠæ¹ã«å¯ŸããççŸ©ç §äŒæ°
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããåŠæ¹ææ¡ã®åæ°ããã³å®æœæéãããŒã ã«ã³ãã¡ã¬ã³ã¹ã®éå¬ç¶
æ³ãå€è·çš®ãšã®çžè«åæ°ããã³çžè«æé
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ£è ã®æªå¿ã»ååã®çºçŸç¶æ³ã®å ±æãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ 人å¡é 眮ã®å€å
ããã»ã¹è©äŸ¡ å¶åå€äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»åž«ãå¶åå€åŠæ¹ã«èŠããæé
å ·äœçãªææã»å¹æ è¬å€åž«ã®å¶åå€ã®ææ¡ã«ãããååå¶åŸ¡çã¯ææã«åäžããã1 幎çåçã
GVHD çºççã«ã¯å·®ããªããã¢ãã¬ãã¿ã³ããå®å šã«å°å ¥ã§ããã
ææçãçºè¡šããåŠäŒ 1) å ç°ãŸããã»ã, é è¡åšè «çã«ãããã¢ãã¬ãã¿ã³ãã®å¹æãšå®å šæ§ã®æ€
èš. 第ïŒïŒåæ¥æ¬å»çè¬åŠäŒè¬æŒèŠæšé, 194 (2011)
2) Ikesue H et al., Antiemetic efficacy and safety of aprepitant in
multiple-day chemotherapy for hematological malignancies. 47th
ASHP Midyear Clinical Meeting and Exhibition, 97 (2012)
ææçãå ±åããè«æã»éèª 1ïŒUchida M et al., Antiemetic effectiveness and safety of aprepitant in
patients with hematologic malignancy receiving multiday
chemotherapy. Am J Health Syst Pharm 70(4): 343-349 (2013)
2ïŒUchida M et al., Effectiveness and safety of antiemetic aprepitant in
Japanesepatients receiving high-dose chemotherapy prior to
autologous hematopoietic stem cell transplantation. Biol Pharm Bull
36(5): 819-824 (2013)
3) Uchida M et al., Efficacy and safety of aprepitant in allogeneic
hematopoietic stem cell transplantation.Pharmacother 33(9):
893-901 (2013)
18
ïŒæ¥åäŸ-â¡ïŒïŒããïŒ
ããŒã å æããå€ã®è¡ç®¡å€æŒåºå¯ŸçããŒã
ããŒã ã圢æããç®ç
æããå€ã®è¡ç®¡å€æŒåºã«ããç®èé害ãåé¿ãããããè¬å€åž«ãææ¡ãã察ç
æ¡ãããšã«åå°éè·ã®é£æºãšæ£è ãžã®å®å šãªæããå€æäžäœå¶ã®æäŸã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æŒåºãäºé²ããããã®æããå€ç¹æ»Žæéãæäžã«ãŒããªã©ã®ææ¡ã»æ å ±æäŸã
æŒåºãªã¹ã¯ãæå°åããæè¬æå°ãè¡ç®¡å€æŒåºæã«ã¯å¯Ÿå¿ãææ¡ïŒæ¥æ¬å»çè¬
åŠäŒ ããå°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ è¡ç®¡å€æŒåºã®çºççãæŒåºæã®ç®è朰ççºçç
ããã»ã¹è©äŸ¡ äºé²æ³ããã³å¯ŸåŠæ³ã«é¢ããããã¥ã¢ã«çã®æšæºåçãæŒåºçºèŠæã®åæ察å¿
ãŸã§ã®æé
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»è¬åæ å ±ãåéè©äŸ¡ãé©åãªå¯Ÿçãå®æœããããã®ã·ã¹ãã ã®æ§ç¯ãã«ã³ã
ã¡ã¬ã³ã¹ã®å®æœãç é¢å šè·å¡ãžã®å¯Ÿçã»äºé²æ³ã®åšç¥
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç®èé害ã®çºçç
ããã»ã¹è©äŸ¡ å»çåŸäºè ã«ããäºåã®èª¬æãæŒåºãªã¹ã¯ãšå¯ŸåŠæ³ãæŽåãããŠããããšã®ç
解åäž
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããå°éè¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åè·çš®ã®äºé²ã»å¯Ÿçã«é¢ããç¥èåäžãæŒåºãªã¹ã¯ã®äœãååŠçæ³ã¬ãžã¡ã³ã®
æŽå
ããã»ã¹è©äŸ¡ è¡ç®¡å€æŒåºãçãããå Žåã®çžè«åæ°ãã«ã³ãã¡ã¬ã³ã¹ãé¢å ç ä¿®äŒãžã®åå
åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ãã£ã³ãµãŒããŒãã§ã®é©æ£ãªæäžæ¹æ³ã®åè°ãã«ã³ãã¡ã¬ã³ã¹ãé¢å ç ä¿®äŒã®
å®æœ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ 蚎èšãªã¹ã¯
ããã»ã¹è©äŸ¡ æ²»çè¬äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»åž«ã»çè·åž«ãæ²»çã«èŠããæé
å ·äœçãªææã»å¹æ æŒåºé »åºŠã¯ 0.14ïŒ ãšé¡èã«äœããç確ãªå¯Ÿå¿ã«ãã£ãŠç®èçç¶ã®é節åãåé¿
ã§ãããå¥ã®ã¬ãžã¡ã³ã§ã¯ãè¬å€åž«ã®ææ¡ã«ããæŒåºïŒä»¶â0 件ã«æžå°ããã
ææçãçºè¡šããåŠäŒ 1) æž¡éè£ä¹ã»ã. å€æ¥ååŠçæ³å®€ã«ãããæããå€ã®è¡ç®¡å€æŒåºå¯Ÿçãžã®é¢
äž.æ¥æ¬è¬åŠäŒç¬¬ 127 幎äŒèŠæšé, 224 (2007)
ææçãå ±åããè«æã»éèª 1) Watanabe H et al., Protection against the extravasation of anticancer
drugs by standardization of the management system. Hospital
Pharmacy 43(7): 571-576 (2008)
2) äŒè€çŸä»£ã»ã, ã¢ã³ãã©ãµã€ã¯ãªã³ç³»æããå€ã®æäžæéã®ççž®ã«ããè¡
管å€æŒåºã®æžå°. æ¥ç è¬èª 45(12): 1613-1615 (2009)
19
ïŒæ¥åäŸ-â¡ïŒïŒç·©åïŒ
ããŒã å ç·©åã±ã¢ããŒã
ããŒã ã圢æããç®ç
身äœçããã³ç²Ÿç¥çãªçç¶ãžã®å»åŠçæ²»çã«å ããŠãããã®çé€å šè¬ã®åé¡ã«
ã€ããŠããå€è·çš®ã¡ã³ããŒã§é£æºããŠæ£è ã家æã«å¯Ÿå¿ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬åŠçã¢ãããŒããè¡ããçç¶ç·©åã«åªãããïŒïŒæ å ±æäŸïŒïŒå蚺åè¡ïŒïŒ
è¬å€åž«ãšã®é£æºïŒïŒæè¬æå°ïŒïŒå»çè ãžæè²ïŒïŒå€æ¥ç·©åã±ã¢ç®¡çãäž»ã«è¡
ãã
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ããæ§çŒçã®é€ççåäž
ããã»ã¹è©äŸ¡ å»çã¹ã¿ãããžã®ããæ§çŒç匷床è©äŸ¡ã®åè
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ çè·åž«ã«ããçµéè¡šãžã®çŒç匷床èšèŒ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ©æåšå® ãžã®ç§»è¡ããã¹ãã¹/ç·©åã±ã¢ç æ£ãžã®è»¢é¢
ããã»ã¹è©äŸ¡ ç 蚺é£æºã®åŒ·å
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ç·©åã±ã¢å°çšçšçŽã«ããæ£è æ å ±æåäž
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç·©åã«é¢ããç¥èåäž
ããã»ã¹è©äŸ¡ ç·©åã«é¢ããæ å ±äº€æ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ¯é± 1 å以äžã®ã«ã³ãã¡ã¬ã³ã¹éå¬ å¹Ž 1 åè¬æŒäŒéå¬
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åçå¢å ãžã®è²¢ç®
ããã»ã¹è©äŸ¡ ç·©åã±ã¢èšºçå ç® å€æ¥ç·©åã±ã¢ç®¡çæ ããæ§çŒçç·©åæå°ç®¡çæ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããŒã ä»å ¥ä»¶æ°
å ·äœçãªææã»å¹æ é€ççãæ¯æïŒåå šç æ£ã§æšªæçã«èª¿æ»ããŠããã2013.10.11 çŸåš 73.8ïŒ ã§
ãããå»çã®è³ªãä¿ãããŠããã
ææçãçºè¡šããåŠäŒ 1) ä¹ ç°çŽçã»ã, è€æ¹ãªãã·ã³ãã³æ³šãç·©åã±ã¢ã§äœ¿çšããïŒïŒïŒãšããœãŒ
ãïŒé¢å åŠæ¹é調æ»ãšæçšæ§è§£æ. 第 1 åæ¥æ¬ç·©åå»çè¬åŠäŒå¹ŽäŒããã°ã©
ã ã»èŠæšé, 62 (2007)
2) ä¹ ç°çŽçã»ã,ç æ£éº»è¬ç®¡çã·ã¹ãã ãçšã㊠Patient controlled
analgesia(PCA)ãè¡ã£ã 13 çäŸ. 第 2 åæ¥æ¬ç·©åå»çè¬åŠäŒå¹ŽäŒããã°
ã©ã ã»èŠæšé, 128 (2008)
3) ç³éç±æš¹ã»ã,ãã§ã³ã¿ãã«ããããããªãã¯ã¹è£œå€ã®ç²çåãšç®èé害:
å¥åº·æ人ãã©ã»ã貌ä»ã«ãããªã¶ãŒããŒè£œå€ãšã®æ¯èŒ. 第 14 åæ¥æ¬ç·©å
å»çåŠäŒåŠè¡å€§äŒèŠæšé, 141 (2009)
ææçãå ±åããè«æã»éèª 1) åæ¬éä»ã»ã, èæ€è»¢ç§»ã®æ¿çã§ãå¯ãããã«ããªã,ãããªã工倫ãšã¯?
æŸå°ç·æ²»çãšåæã«è¡ã£ã Tilt table ç«äœä¿æèšç·Žãæå¹ã ã£ã 1 äŸ. ãã¹
ãã¹ã±ã¢ãšåšå® ã±ã¢ 17(2): 185 (2009)
2) åæ¬éä»ã»ã, ããæ§çŒçã«ãããè€æ¹ãªãã·ã³ãã³æ³šæç¶ç®äžæ³šã®æå¹
æ§ãšå®å šæ§-éå» 4 幎éã®åŠæ¹èª¿æ». çãšååŠçæ³ 36(10): 1683-1689
(2009)
3) åæ¬éä»ã»ã,ããæ§çŒçæ²»çãç®çãšããè€æ¹ãªãã·ã³ãã³æ³šå°æ¶²ã®æå¹
æ§ãšå®å šæ§-å€æœèšã§ã®åŠæ¹èª¿æ»-. çãšååŠçæ³ 37(5): 871-878 (2010)
20
ïŒæ¥åäŸ-â¡ïŒïŒææïŒ
ããŒã å ICT
ããŒã ã圢æããç®ç
æ£è ãè·å¡çãææçãªã¹ã¯ããå®ããç é¢ææã®é²æ¢ã«çæãææççºçã®
å Žåã«éãããªç¹å®ïœ¥å¶å§ïœ¥çµæ¯ãå³ãäºã¯å»çæäŸæœèšã«ãšã£ãŠéèŠã§ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æèè¬ã®äœ¿çšç¶æ³ã®ææ¡ã䜿çšã«é¢ããå©èš (æ¥æ¬ç é¢è¬å€åž«äŒ ææå¶åŸ¡
å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æèè¬é©æ£äœ¿çšã«ããæ²»çã®æé©å(èµ·å èã«å¿ããè¬å€éžæã§äœ¿çšéäœäžïŒ
èæ§èã®çºçé²æ¢
ããã»ã¹è©äŸ¡ TDM å®æœç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é»åã«ã«ãããŒã¿ããåŠæ¹è¬ã®æœåºãæ£è ããŒã¿åç §
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ 䜿çšè¬å€ å ¥é¢æé èæ§èã®çºçé²æ¢
ããã»ã¹è©äŸ¡ æ²»çå¹æã«ããå®æ¥œãªçé€
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ICT ã©ãŠã³ãã«ããç°å¢æŽåãææè¡çã®æå°ã«ããææçãªã¹ã¯
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ææçã«å¯Ÿããã¹ã¿ããã®æèåäžå°éã»èªå®è³æ Œå¶åºŠã«ããå°éæ§åäž
ããã»ã¹è©äŸ¡ è¬æŒäŒåå 人æ°ã®ææ¡ããã³æºè¶³åºŠã¢ã³ã±ãŒããåçš®ã³ã³ãµã«ããŒã·ã§ã³
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ICT ã©ãŠã³ããå®æè¬æŒäŒã®å®æœ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¬å€è²»
ããã»ã¹è©äŸ¡ æèè¬äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ åŸçºåå°å ¥ã䜿çšå±åºå¶ã«ããæèè¬é©æ£äœ¿çšãã¢ãŠããã¬ã€ã¯ã«å¯Ÿããçµè²»
å ·äœçãªææã»å¹æ
1ïŒ 2008 幎 1 æã«æçèè¬äœ¿çšçç±æžå±åºå¶ãå°å ¥ãã1 ãµæåœããå¹³å AUD
ã¯å±åºå¶ååŸã§ 12.8±1.8 ãã 7.6±1.8 ãžãšææã«ïŒpïŒ0.01ïŒæžå°ãã
é·ææäžæ£è ã®å¹³åæäžæ¥æ°ãæ¯èŒãããš 23.6±15.8 æ¥ãã 18.7±10.0
æ¥ãžãšææïŒpïŒ0.05ïŒã«ççž®ããè¬å€è²»åæžå¹æ㯠2370 äžåã«æã£ãã
2) ç¹å®æèè¬ïŒæ MRSAã«ã«ãããã ç³»è¬ïŒäœ¿çšçç±æžå±åºå¶ãå°å ¥ïœ€2008
幎 2 æã«å šæ MRSA è¬ã®äœ¿çšéå§æããå±åºå¶ãå°å ¥ãå 容ãæ¹å®ããã
æ¹å®ã§æèè¬äœ¿çšéã¯æžå°ãè¬å€è²»åæžå¹æã¯å¹Žé 1970 äžïœ2940 äžãš
æšå®ãããã
3) ãšã¿ããŒã«å«ææææ¶æ¯è¬ã®äœ¿çšæãã¹ããå®æœããæ¶æ¯è¬ã®èŠçŽããšå ±
ã«é¢å ã®ç ä¿®ãã«ã³ãã¡ã¬ã³ã¹ãéããŠææè¡çæè²æšé²ãå³ã£ããæ¶æ¯è¬
å€æŽåŸã¯æ¶æ¯è¬è«æ±éãå¢å ãããšå ±ã« MRSA æ€åºçãæžå°ããã
ææçãçºè¡šããåŠäŒ 1) ç°äžäº®è£ã»ã, æ MRSA è¬äœ¿çšéã«åãŒãææå¶åŸ¡éšã«ããä»å ¥ã®åœ±é¿.
第 19 åå»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 359 (2009)
2) æž¡éçäžã»ã, æèè¬é©æ£äœ¿çšã«åããæçèè¬äœ¿çšå±åºå¶ã®å°å ¥. 第 57
åæ¥æ¬ååŠçæ³åŠäŒè¥¿æ¥æ¬æ¯éšç·äŒè¬æŒèŠæšé (2009)
3) ç°äžäº®è£ã»ã, æ MRSA è¬é©æ£äœ¿çšã®åãçµã¿ãš TDMã®æŽ»çš. å»çè¬åŠã
ã©ãŒã©ã è¬æŒèŠæšé, 90 (2011)
ææçãå ±åããè«æã»éèª 1) ç°äžäº®è£ã»ã, æ MRSA è¬äœ¿çšéã«åãŒãææå¶åŸ¡éšã«ããä»å ¥ã®åœ±é¿.
å»çè¬åŠ 36(4): 232-239 (2010)
2) ç°äžäº®è£ã»ã, æèè¬é©æ£äœ¿çšã«åãã泚å°æçèè¬äœ¿çšå±åºå¶ã®è©äŸ¡.
å»çè¬åŠ 36(6): 392-396 (2010)
21
ïŒæ¥åäŸ-â¡ïŒïŒææïŒ
ããŒã å ICT
ããŒã ã圢æããç®ç
æ£è ãç é¢è·å¡ã«å®å šãªå»çãæäŸããããã®åºç€ã§ããææ察çã¯ç é¢å šäœ
ã§åãçµãå¿ èŠããããããææ察çã«é¢ããå»çè ãååããããŒã ã圢æ
ããããšãäžå¯æ¬ ã§ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æèè¬ã®åŠæ¹éææ¡ãé·æåŠæ¹äŸã®ææ¡ã»ä»å ¥ãæ¶æ¯è¬ã®ç®¡çãïŒå®æœã«
ããåŠæ¹èšèšã»ææ¡ãææå¶åŸ¡éšã®å°ä»»ïŒå ïŒæ¥æ¬ç é¢è¬å€åž«äŒ ææå¶åŸ¡
å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ å»çé¢é£ææã®çºçç èæ§èã®çºçé²æ¢
ããã»ã¹è©äŸ¡ æèè¬äœ¿çšå±ã®æåºçãæèè¬é·ææäžçäŸãžã®ä»å ¥ãæ¶æ¯è¬ã®é©æ£äœ¿çš
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ é¢å ã©ãŠã³ããä»æœèšãšã®ååã«ã³ãã¡ã¬ã³ã¹ã»çžäºãã§ãã¯ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ææççºççã»æ©ææ²»ççã»äœ¿çšè¬å€ã®æžå°èæ§èã®çºçé²æ¢
ããã»ã¹è©äŸ¡ æ²»çå¹æã«ããå®æ¥œãªçé€
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææçãªã¹ã¯
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ææçããã³ç°å¢è¡ççã«é¢ããã³ã³ãµã«ããŒã·ã§ã³
ããã»ã¹è©äŸ¡ ä»è·çš®ããã®ã³ã³ãµã«ããŒã·ã§ã³åæ°ãïŒå®æœç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ïŒã«ããæèè¬ã®åŠæ¹ææ¡ãå匷äŒã®å®æœ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ ææé²æ¢å¯Ÿçå ç®ç®å®ä»¶æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã¢ãŠããã¬ã€ã¯ã«å¯Ÿããçµè²»
å ·äœçãªææã»å¹æ åœé¢ã¯ïŒïŒ²ïŒ³ïŒ¡ã®åé¢é »åºŠã 23.8ïŒ ãšäœãããŸããæèè¬äœ¿çšé調æ»ãé·æåŠ
æ¹äŸãžã®ä»å ¥çã®æèè¬é©æ£äœ¿çšã®æšé²ã«ãããïŒã«å¯Ÿããç·è¿èèæ§ç
ã 10.8ïŒ ã§ããã
ææçãçºè¡šããåŠäŒ 1) æ£®å Œå倪ã»ã, ïŒïŒ²ïŒ³ïŒ¡ã®ç©æ¥µçç£èŠå¹é€ã®å¹æ. 第 26 åæ¥æ¬ç°å¢ææåŠ
äŒç·äŒ, 305 (2011)
2) å¯æ°žç¶Ÿã»ã, è¬ç©è¡äžæ¿åºŠæž¬å®æ³å€æŽæã®è©äŸ¡ãšãã³ã³ãã€ã·ã³è¡äžæ¿åºŠ
枬å®ã®åé¡ç¹. å»çè¬åŠãã©ãŒã©ã 2011/第 19 åã¯ãªãã«ã«ãã¡ãŒãã·
ãŒã·ã³ããžãŠã , 202 (2011)
3) 现谷é ã»ã, 泡ç¶ã¹ã¯ã©ã補å€ã®æææ¶æ¯å¹æãåŸæ¥åãšã®æ¯èŒããã³äœ¿çš
éã«ããé€èå¹æã®æ¯èŒ. 第 28 åæ¥æ¬ç°å¢ææåŠäŒç·äŒ, 460 (2013)
ææçãå ±åããè«æã»éèª 1) 现谷é ã»ã , è¬åŠçã察象ãšããææè¡çå®ç¿ã®æå¹æ§ . æ¥ç è¬èª
46(11): 1496-1500 (2010)
2) è±å£çŠåã»ã, ãã³ã³ãã€ã·ã³ PK/PD ãã©ã¡ãŒã¿ãŒå€åãšæ害åå¿. å»ç
è¬åŠ 36(6): 419-424 (2010)
3) å¯æ°žç¶Ÿã»ã, 枬å®æ³ã«ããè¬ç©è¡äžæ¿åºŠãžã®åœ±é¿ãšéæã®æç¡ã«ãããã³
ã³ãã€ã·ã³è¡äžæ¿åºŠã®éã. æ¥ç è¬èª 48(9): 1117-1120 (2012)
22
ïŒæ¥åäŸ-â¡ïŒïŒç²Ÿç¥ïŒ
ããŒã å ããåŠã±ã¢ããŒã
ããŒã ã圢æããç®ç
æ²»çãã±ã¢ã®å å®ãå³ãããšã§ãæ©æã«ããåŠããå埩ããåçŸæ£æ²»çãžã®å°
念ãç®æãããŸããæ²»çãã±ã¢ã·ã¹ãã ã®æ§ç¯ã»æŽåã»å®æœã»è©äŸ¡ãè¡ã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
䜿çšè¬å€ã®å¯äœçšã泚æç¹ãè¬ç©åæ ãè¬ç©çžäºäœçšã«ã€ããŠã®æ å ±æäŸãã
ãåŠèªçºè¬ã®æ¢çŽ¢ãåŠæ¹æ¡ã®æ瀺
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æ粟ç¥ç è¬ã®é©æ£äœ¿çšãç¶æ³ã«åãããã±ã¢å 容ã®èŠçŽã
ããã»ã¹è©äŸ¡ è¬å€æ å ±åã³ã±ã¢ã®å ±æ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ 䜿çšè¬å€äžèŠ§è¡šã®äœæãã«ã³ãã¡ã¬ã³ã¹å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¬å€æäžéã®èª¿æŽãšã±ã¢å 容ã®ä¿®æ£ãæ£è QOLã»å®å šæ§ã®åäž
ããã»ã¹è©äŸ¡ å蚺åŸã®æ£è 蚪åãè¬å€è©äŸ¡ãã±ã¢å 容ã®èŠçŽã
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å蚺åŸã®ãµããŒãäœå¶ã®å å®
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ããŒã ã¡ã³ããŒä»¥å€ã®ç¥èã»æè¡ã®åäž
ããã»ã¹è©äŸ¡ ããŒã å ã§åŸãç¥èã»æè¡ã®åéšçœ²ãžã®æ®åãšæ å ±ã®å ±æå
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å匷äŒãäºäŸæ€èšäŒã®å®æœãšã±ã¢ã·ã¹ãã ã®æ§ç¯
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ 粟ç¥çç¶ã®è©äŸ¡çã«ä¿ãå蚺ãå®æœ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ 粟ç¥ç§ãªãšãŸã³ããŒã å ç®ã®ç®å®ãšå ¥é¢ç²Ÿç¥çæ³å ç®ã®ç®å®
å ·äœçãªææã»å¹æ 1ïŒå蚺å®çžŸïŒå蚺察象è ïŒïŒå¹³æ 20 幎床 479 åãå¹³æ 21 幎床 470 åãå¹³æ
22 幎床 440 åãå¹³æ 23 幎床 506 åãå¹³æ 24 幎床 562 å
2ïŒå蚺éå§ 1 幎åŸã®ç æ£ãžã®è³ªåçŽèª¿æ»ïŒãããåŠäºé²ãžã®æèãé«ãŸã£ããã
ãããåŠãçžè«ã§ããå®å¿æãçãŸãããçãæãããšãªã£ã
ææçãçºè¡šããåŠäŒ 1) å å·æ¶è£ã»ã, ããåŠçºçæã®ã¹ã ãŒãºãªå¯ŸåŠãç®æããŠïœçè·åž«ãšã®çž
äºååããã³åŠæ¹è¬ãžã®é¢ããïœ.第 29 åæ¥æ¬ç é¢è¬å€åž«äŒè¿ç¿åŠè¡å€§äŒ
èŠæšé, 218 (2008)
2) å å·æ¶è£ã»ã, ããŒã ã§åãçµãããåŠå¯Ÿçïœçè·åž«ãšè¬å€åž«ãšã®çžäºå
åïœ.第 3 åå»çã®è³ªã»å®å šåŠäŒåŠè¡éäŒèŠæšé, 278 (2008)
3) å å·æ¶è£ã»ã, ãããåŠã§å°ã£ãŠããŸãããïŒãïœããåŠå蚺 5 幎ã®æ©ã¿
ïœ.第 32 åæ¥æ¬ç é¢è¬å€åž«äŒè¿ç¿åŠè¡å€§äŒèŠæšé, 195 (2011)
4) å å·æ¶è£ã»ã, å€§è ¿éªšé éšéªšææ£è ã®ããåŠã«å¯Ÿããå挢蚺çã®æå¹æ§ã«
ã€ããŠã®æ€èš.第 33 åæ¥æ¬ç é¢è¬å€åž«äŒè¿ç¿åŠè¡å€§äŒèŠæšé,93(2012)
5) å å·æ¶è£ã»ã, å€§è ¿éªšé éšéªšææ£è ãžã®æŒ¢æ¹è¬ãçšããããåŠæ²»çã®æçš
æ§ã«é¢ããæ€èš.第 22 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒèŠæšé, 358 (2012)
ææçãå ±åããè«æã»éèª 1) å å·æ¶è£ã»ã, ããŒã ã§åãçµãããåŠå¯Ÿçïœçè·åž«ãšè¬å€åž«ãšã®çžäºå
åïœ.å»çã®è³ªã»å®å šåŠäŒèª 4(1): 75-85 (2009)
2) å å·æ¶è£ã»ã, ãããåŠå蚺ãã«ãããè¬å€åž«ã®æŽ»åãšåœ¹å²æ¡å€§. çè·ç®¡ç
21(3): 230-231 (2011)
23
ïŒæ¥åäŸ-â¡ïŒïŒè€¥ç¡ïŒ
ããŒã å 耥ç¡å¯ŸçããŒã
ããŒã ã圢æããç®ç
耥ç¡è©äŸ¡ã«ïŒ€ïŒ¥ïŒ³ïŒ©ïŒ§ïŒ®ïŒïŒ²ãçšããŠå€è·çš®ååã«ããããŒã å»çãå®è·µãã
耥ç¡ã®æ©ææ²»çãç®æãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
耥ç¡æ²»çè¬ã»ãã¬ãã·ã³ã°æã®è©äŸ¡ã»ææ¡ãïŒïŒ²è©äŸ¡ãšé»åã«ã«
ããžã®è©äŸ¡å ¥åã耥ç¡ã«é¢ããããŒã¿ã®åéã»è§£æãæ é€è©äŸ¡ ïŒæ¥æ¬è€¥ç¡åŠ
äŒ èªå®å£«ïŒè¬å€åž«ïŒãæ¥æ¬éèçµè žæ é€åŠäŒ æ é€ãµããŒãããŒã å°éçæ³å£«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ 耥ç¡çºççã耥ç¡ã®æ©ææ²»ç
ããã»ã¹è©äŸ¡ ïŒïŒ²ãçšããè¬å€åž«ã«ãã耥ç¡è©äŸ¡ãNST å°éçæ³å£«ïŒè¬å€åž«ïŒ
ã«ããæ é€è©äŸ¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ¥æ¬è€¥ç¡åŠäŒèªå®å£«ïŒè¬å€åž«ïŒãNST å°éçæ³å£«ïŒè¬å€åž«ïŒã®é 眮ãå®æçãª
耥ç¡å蚺ãã«ã³ãã¡ã¬ã³ã¹ã®éå¬
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ 耥ç¡ã®æ©ææ²»çã耥ç¡ã®çºçäºé²ãäœæ é€ç¶æ ã®æ¹åã»äºé²
ããã»ã¹è©äŸ¡ æ¥æ¬è€¥ç¡åŠäŒèªå®å£«ïŒè¬å€åž«ïŒã«ãã耥ç¡å蚺åå ãNST å°éçæ³å£«ïŒè¬å€åž«ïŒ
ã® NST ã«ã³ãã¡ã¬ã³ã¹ãžã®åå
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ¥æ¬è€¥ç¡åŠäŒèªå®å£«ïŒè¬å€åž«ïŒãNST å°éçæ³å£«ïŒè¬å€åž«ïŒã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§åäžã耥ç¡åŠçœ®ã»è©äŸ¡ã®å¹çå
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ãã耥ç¡åŠçœ®ã»è©äŸ¡ã耥ç¡å¯ŸçããŒã ãšïŒ®ïŒ³ïŒŽã®å¹æçãªé£æº
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å®æçãªããŒã ã«ã³ãã¡ã¬ã³ã¹ã®éå¬ãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ 耥ç¡ã®æ©ææ²»çã«ããåè·çš®ã®åŽååã耥ç¡æ²»çè¬ãšãã¬ãã·ã³ã°æã®é©æ£äœ¿
çšã«ããã³ã¹ã
ããã»ã¹è©äŸ¡ 耥ç¡æ²»çè¬ãšãã¬ãã·ã³ã°æã®é©æ£äœ¿çšã®æšé²
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ¥æ¬è€¥ç¡åŠäŒèªå®å£«ïŒè¬å€åž«ïŒãNST å°éçæ³å£«ïŒè¬å€åž«ïŒã®é 眮
å ·äœçãªææã»å¹æ 1) DESIGN-R åèšç¹ãšè€¥ç¡æ²»çæ¥æ°ã®é¢ä¿ãããDESIGN-R åèšç¹ 14 ç¹ä»¥
äžã§ããã° 90.9%ïŒ60/66ïŒã 38 æ¥æªæºã«æ²»çããDESIGN-R åèšç¹ 14
ç¹ãè¶ ãããš 85.7%ïŒ12/14ïŒãæ²»çãŸã§ 38 æ¥ä»¥äžãããããšãäºæž¬ã
ããã
2) è¬å€åž«ã®ç©æ¥µçãªåç»ã«ãã£ãŠã耥ç¡æ²»çè¬ãšãã¬ãã·ã³ã°æã®é©æ£äœ¿çš
ã«è²¢ç®ã§ãããè¬å€åž«ãäžå¿ãšãªã£ãŠæŽ»åããããšã§ã耥ç¡å¯ŸçããŒã ãšïŒ®
ã«ããå¹æçãªé£æºãè¡ããããã«ãªã£ãã
ææçãçºè¡šããåŠäŒ 1) é¶Žå± åä¹ã»ãïŒè€¥ç¡å¯ŸçããŒã ã§ã®è¬å€åž«ã®åœ¹å²ïŒç¬¬ 20 åæ¥æ¬å»çè¬åŠäŒ
幎äŒè¬æŒèŠæšéïŒ20ïŒ466ïŒ2010ïŒ
2) é¶Žå± åä¹ã»ãïŒé床耥ç¡ãžã® NST ãšè€¥ç¡å¯ŸçããŒã ã®é£æºïŒæ¥æ¬è€¥ç¡åŠäŒ
èª 13(3): 414ïŒ2011ïŒ
3) é¶Žå± åä¹ã»ãïŒ DESIGN-R åèšç¹ãææšãšãã耥ç¡æ£è ãžã®ããŒã å»çïŒ
第 40 åå¯å±±çåœä¿å°åå»çåŠäŒããã°ã©ã , 3ïŒ2012ïŒ
ææçãå ±åããè«æã»éèª 1) é¶Žå± åä¹ã»ãïŒé»åã«ã«ãã»è€¥ç¡ã±ã¢ã·ã¹ãã ã掻çšãã耥ç¡ã±ã¢ããŒã
ãžã®è¬å€åž«åå ã®æçšæ§ïŒå»çè¬åŠïŒ31(9): 714-722ïŒ2005ïŒ
2) é¶Žå± åä¹ã»ãïŒDESIGN-R åèšç¹ãææšãšãã耥ç¡å¯ŸçããŒã ãš NST ã®å¹
æçãªé£æºïŒæ¥æ¬è€¥ç¡åŠäŒèªïŒ14(4): 577-581ïŒ2012ïŒ
24
ïŒæ¥åäŸ-â¡ïŒïŒïŒ®ïŒ³ïŒŽïŒ
ããŒã å æ é€ãµããŒãããŒã
ããŒã ã圢æããç®ç
æ é€é害ãªã¹ã¯ã®é«ãæ£è ã«å¯ŸããŠãNST ãµããŒããè¡ãããšã«ãããåå°é
è·çš®ã®ç¥èãæè¡ãæ é€çæ³ã«åãå ¥ãããæ£è ã®æ é€ç¶æ ãè©äŸ¡ãææ¡ãã
äžã§ãé©åãªæ é€çæ³ãè¡ãªããææçãªã©ã®å䜵çãäºé²ããæ©ææ²»çã»æ©
æéé¢ã«çµã³ä»ããããŸããé¢å ã«ãããŠãæ é€çæ³ã«é¢ããç¥èãæ®åãã
ãããšã«ãããç é¢ãšããŠã®å»çã®è³ªãåäžããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬æŽãæ£è æ å ±ã確èªããæ é€çæ³ãè¡ãäžã§é害ãšãªãè¬å€ã®å¯äœçšã®æç¡
ããã§ãã¯ãå»è¬åã®é©æ£äœ¿çšã«é¢ããŠåŠæ¹ææ¡ãåŠæ¹æ¯æŽçãè¡ããçµè žæ
é€ã»éèæ é€ã¡ãã¥ãŒå 容ã«ã€ããŠãä¿®æ£å€æŽãå¿ èŠãšæãããæã«ã¯ãæšå¥š
ã¡ãã¥ãŒå 容ã®ææ¡ãè¡ãããããã®æ å ±ã«é¢ããŠãè¬å€éšå ã«åšç¥ãããã
ïŒæ¥æ¬éèçµè žæ é€åŠäŒ æ é€ãµããŒãããŒã å°éçæ³å£«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ éäžæ²»ç宀ã®åšé¢æ¥æ°ãããã¯è¡åŸåšé¢æ¥æ°ã®ççž®ãå䜵çã®çºççã®æžå°ã
æ»äº¡çã®æžå°ãæ é€çŽ æã®é©æ£äœ¿çšïŒé©æ£ãªçµè žã»éèæ é€å€ã®éžæïŒã«ãã
çµè žæ é€å€å®æœçã®åäž
ããã»ã¹è©äŸ¡ å»è¬åé©æ£äœ¿çšã®æšé²ãéèæ é€ã¡ãã¥ãŒã®èŠçŽã
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ãšå蚺ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ©ææ²»ççãææçãªã©ã®å䜵çã®çºçç
ããã»ã¹è©äŸ¡ å®æçãªæ é€ç¶æ ã®è©äŸ¡ãæ é€æå°ã®ç©æ¥µçãªä»å ¥
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æåéã®èŠ³å¯èšé²ã®åŸ¹åºãæ䟿ç¶æ³ã®èšé²ã®åŸ¹åº
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§ã®åäž
ããã»ã¹è©äŸ¡ ç ä¿®ã®å®æœãåŠäŒèªå®è³æ Œã®ååŸãããŒã éã§ã®æ å ±äº€æ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è¬ç¿äŒãå匷äŒã®å®æœãã«ã³ãã¡ã¬ã³ã¹åã³å蚺ãžã®åå ååäœå¶
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»è¬åã®é©æ£äœ¿çšãšå䜵çäºé²ã«ããå»çè²»ã®åæžãæ é€çŽ æã®é©æ£åã«ãã
å»çè²»åæžãNST å ç®
ããã»ã¹è©äŸ¡ ããŒã å»çå ç®ç®å®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°åŸè ããã³å°ä»»è ã®ç¢ºä¿
å ·äœçãªææã»å¹æ 1) èèªä¹³å€ã®æäžé床ã«é¢ããŠãNST äž»å°ã®ããšãåŠæ¹æ¯æŽãæšå¥šé床æ©èŠ
è¡šã®äœæãè¡ããããããŠå»çåŸäºè ãžã®æè²ãè¡ãããšã«ãããèèªä¹³
å€ã®æäžé床ã¯é©æ£åããããïŒïŒè¬å€åž«ãé«ã«ããªãŒèŒžæ¶²ã¡ãã¥ãŒå 容
ããã§ãã¯è©äŸ¡ããå¿ èŠã«å¿ããŠãNST äž»å°ã®ããšåŠæ¹æ¯æŽãè¡ãããšã«
ãããç³è³ªéå°ã®äºé²ãå¿ èŠã¢ããé žã®æåãé»è§£è³ªãã©ã³ã¹ã®ç¶æãªã©
ã«è²¢ç®ã§ããã
ææçãçºè¡šããåŠäŒ 1) ææšæåã»ã, è¬å€åž«ã®ç©æ¥µä»å ¥ã«ããèèªä¹³å€æäžé床ã®é©æ£åã«ãã
ãææ. 第 25 åæ¥æ¬éèçµè žæ é€åŠäŒæé²é 25(1): 469 (2010)
2) ææšæåã»ã, è¬å€åž«æ¥åãšNSTãšã®é£æº. 第26åæ¥æ¬éèçµè žæ é€åŠäŒ
æé²é 26(1): 468 (2011)
25
ïŒæ¥åäŸ-â¡ïŒïŒææ¥ã»éäžïŒ
ããŒã å ER åæåœææ¥ã»ã³ã¿ãŒã±ã¢ããŒã
ããŒã ã圢æããç®ç
æ£è ã®ç¶æ ãæ²»çæ¹éãå€è·çš®ãå ±æãããšãšãã«ãåå°éè·ãèªäž»æ§ãæã£
ãŠåœ¹å²ãæããããšã«ããã質ã®é«ãå»çã®å®çŸããã³å»çã¹ã¿ããã®ç¥èå
äžãç®æãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬ç©æ²»çèšç»ã®ææ¡ãå»è¬åããã³èšºçäžã®åé¡è§£æ±ºã®ããã®æ å ±æäŸïŒè¬å€
ã«é¢ãããã®ïŒãçœå®³æã«ãããæ¯æŽ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ åšå®€æ¥æ°ãã€ã³ã·ãã³ãã»ã¢ã¯ã·ãã³ãçºççãçœå®³ææè·ç掟é£åæ°
ããã»ã¹è©äŸ¡ æ²»çæ¹éææ¡åæ°ãæ å ±æäŸåæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥å°ä»»è¬å€åž«ãå«ãå°éè·çš®ã®åå ãé»åã«ã«ããéçéšéã·ã¹ãã çã«ã
ãæ å ±å ±æãè¬å€åž«ãå«ãçœå®³å»çããŒã ã®äœå¶æŽå
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åšå®€æ¥æ°ãQOL ã®åäž
ããã»ã¹è©äŸ¡ å¯äœçšã»ããåŠçºççãæ£è ããŒãºã®èŽååæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥å°ä»»è¬å€åž«ãå«ãå°éè·çš®ã®åå ãçœå®³æã®å»çæäŸäœå¶ã®æç¡
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«ã»çè·åž«ã®è² æ ãåè·çš®ã®å°éç¥èã®æŽ»çšåºŠ
ããã»ã¹è©äŸ¡ äºåã«äœæãåæããããããã³ã«ã«åºã¥ãè¬ç©æ²»çã®å®æœåæ°ãææ¡å 容ã®
æ²»çãžã®åæ çãåè·çš®ããã®è³ªååæ°ãçœå®³å»ç掟é£ã®ã¹äººæ°ã
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥å°ä»»è¬å€åž«ãå«ãå°éè·çš®ã®åå ãçœå®³æã®å»çæäŸäœå¶ã®æç¡
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ å»è¬åã»èšºçææ䜿çšéé¡ãåšå®€æ¥æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ DPC å°å ¥ãå»çã¹ã¿ããã®ä¿éºèšºçç¥èç¿åŸ
å ·äœçãªææã»å¹æ 1) 2011 幎 7 æãã 2012 幎 5 æãŸã§ã«ãã®ã¹ 393 人㮠ICU å ¥å®€æ£è ã®å蚺
ã«åå ãã119 件ã®ææ¡ã質åãžã®åçã課é¡ã®è§£æ±ºãªã©ã®æ¥åãè¡ã£ãã
ãã®å 容ã¯çŠå¿ã®æ³šæåèµ·ãå¯äœçšã®é²æ¢ãçŸåšã®ç æ ãšè¬ç©æ²»çãšã®é¢ä¿
ã®è©äŸ¡ãªã©ãè¬ç©æ²»çãå®å šã«å®æœããããã®å 容ãäžå¿ã§ãã£ãã
2) çœå®³å»çã«ããããå»è¬åé絊ã«é¢ãã課é¡ããã³æ å ±å ±æ掻åã®æçšæ§
ã瀺ãããã
ææçãçºè¡šããåŠäŒ 1) äžæµŽäŒžäºã»ã, æåœææ¥ã»ã³ã¿ãŒã«ãããè¬å€åž«ã®åœ¹å². 第 15 åæ¥æ¬èšåº
ææ¥å»åŠäŒç·äŒã»åŠè¡éäŒ ããã°ã©ã ã»æé²é, 192 (2012)
ææçãå ±åããè«æã»éèª 1) äžæµŽäŒžäºã»ãïŒå€§èŠæš¡çœå®³è¢«çœå°ã«å¯Ÿããå»çæ¯æŽ-æè·æã«ãããåŠæ¹å
åãšã°ã«ãŒãããŒãžã掻çšããåŸæ¹æ¯æŽ-ïŒæ¥èšæå»èª 16(4): 589-594
(2013)
26
ïŒæ¥åäŸ-â¡ïŒïŒææ¥ã»éäžïŒ
ããŒã å ææ¥ã»éäžæ²»çé åïŒé«åºŠæåœææ¥ã»ã³ã¿ãŒã»ICUã»HCUïŒã±ã¢ããŒã
ããŒã ã圢æããç®ç
ææ¥ã»éäžæ²»çé åã«ãŠã䟵襲åŠãäžæ¯å»çãªã©ææ¥ã»éäžæ²»çé åã®ç¹æ§ã
èæ ®ããè¬ç©çæ³ã®æäŸã«ããå»çã®è³ªçåäžãç®çãšããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
å ¥å®€æã®è¬æŽè©äŸ¡ã»åŠæ¹ç£æ»ã»è¬å€éžæã»åŠæ¹èšèšã»å¹æããã³å¯äœçšã¢ãã¿
ãªã³ã°ãªã©è¬åŠç管çãè¬å管çïŒæ¥æ¬èšåºææ¥åŠäŒ ææ¥èªå®è¬å€åž«ãæ¥æ¬
äžæ¯åŠäŒ ã¯ãªãã«ã«ã»ããã·ã³ããžã¹ãïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ è¬å€åž«ããã®æ å ±æäŸã«ããæ²»çæ¹éããã³æ°èŠåŠæ¹ã»åŠæ¹å€æŽãªã©ã®æ±ºå®ã
å¯äœçšçºçŸã»é節åé²æ¢ãçŸæ£ã®æ©æ軜快ã
ããã»ã¹è©äŸ¡ æ å ±æäŸã»ãã£ã¹ã«ãã·ã§ã³ã®å 容ã»ä»¶æ°ãïŒãªãŒã件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°éè¬å€åž«ã®é 眮ãã«ã³ã¢ã¬ã³ã¹ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¬ç©çæ³ã«ãããå¹æã»å¯äœçšãé«åºŠæåœææ¥ã»ã³ã¿ãŒã»ICUã»HCU åšå®€æ¥æ°
ããã»ã¹è©äŸ¡ ãã¬ã¢ãã€ãå ±å件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ïŒåºãããã®è¬å€åž«æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ææ¥ã»éäžæ²»çé åã®ç¹æ§ãèæ ®ããè¬åŠç管çã®è³ª
ããã»ã¹è©äŸ¡ ææ¡ã«å¯Ÿããæ¿è«Ÿçããã³æ²»çãžã®åæ çãå»çã¹ã¿ããããã®çžè«ä»¶æ°
è¬å€åž«ã«ããïŒãªãŒã件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ²»çæ¹éã®å ±æãã«ã³ãã¡ã¬ã³ã¹ã»å匷äŒã®å®æœ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¬å€è²»ãç é¢åç
ããã»ã¹è©äŸ¡ è¬å€è²»ãåšå®€æ¥æ°ãè¬å€ç®¡çæå°ä»¶æ°ãç æ£è¬å€æ¥åå®æœå ç®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥ã»éäžæ²»çå°åŸè¬å€åž«ã®é 眮
å ·äœçãªææã»å¹æ 1) è¬å€åž«ãåžžé§ããŠãå ¥å®€æè¬æŽè©äŸ¡ãæ§ã ãªæ å ±æäŸãè¡ãã蚺æã»æ²»ç
æ¹éã®æ±ºå®ããã³è¬ç©çæ³ã«åç»ããæçšæ§ã瀺ãããã
2) TEIC æäžã«åœãããéäžæ²»çé åã«ãããŠã¯ãæ·»ä»ææžã«åŸã£ãçšæ³çšé
ã§ã¯ãè³é©è¡äžæ¿åºŠã«éããªãããšã瀺ãããã
3) äžæ¯å»çã«ãããè¬å€åž«ã«ããæ¯æŽäœå¶ã®æãæ¹ã瀺ãããã
ææçãçºè¡šããåŠäŒ
1) æªæµŠå å¥ã»ã, åœé¢æåœã»ã³ã¿ãŒã«ãããèªæ®ºäŒå³çäŸã«ãããæè¬ã»ææ¯
æ£è ã®çŸç¶. 第 31 åæ¥æ¬äžæ¯åŠäŒç·äŒã»åŠè¡éäŒçºè¡šæé² äžæ¯ç 究,
22:359 (2010)
2) 倧å£äŸåã»ã, åœé¢é«åºŠæåœææ¥ã»ã³ã¿ãŒã«ãããèºèåºè¡çäŸã®æ€èš.
第 20 åæ¥æ¬å»çè¬åŠäŒè¬æŒèŠæšé, 417 (2010)
3) ç¯ åæž çŸã»ã, è¡äžæ¿åºŠäžæã®é 延ãææ¡ãäžæ¯çç¶ã«å¯Ÿå¿ã§ããããªã
ã£ãªã³å€§éæçšã® 2 çäŸ. 第 34 åæ¥æ¬äžæ¯åŠäŒç·äŒã»åŠè¡éäŒçºè¡šæé² äž
æ¯ç 究, 25:371 (2012)
ææçãå ±åããè«æã»éèª
1) çäºæµ©åã»ã, è¬å€åž«ãææ¥å»çã«åç»ããæ矩 ïŒDDS çå矀çäŸã®çµ
éšãããŒ. æ¥ææ¥å»äŒèª 13(7): 377-380 (2002)
2) äºåä¹ çŸåã»ã, è¬å€åž«ã«ããæ¥æ§è¬æ¯ç©äžæ¯æ£è ã®æ²»çæ¯æŽæŽ»åäœç³»ã®
ç¢ºç« -æ å ±ç®¡çãšèµ·å ç©è³ªåå®ã®ããã«ïœ°. äžæ¯ç 究 16(4): 433-440
(2003)
3) 森å·èšéã»ã, éäžæ²»çé åã«ããããã€ã³ãã©ãã³ã®çšæ³çšéã®æ€èš.
æ¥éäžå»èª 15(4): 509-514 (2008)
27
ïŒæ¥åäŸ-â¡ïŒïŒææ¥ã»éäžïŒ
ããŒã å ææ¥å»çããŒã
ããŒã ã圢æããç®ç
ææ¥æ£è ã¯èåšæ©èœãå«ãå€çš®å€æ§ãªç æ ãåãããããäœçšãæ¥æ¿ãªæ³šå°å€
ãæ§ã ãªå»çæ©åšã«ãŠæäžãããå°åŸåå€è·çš®ããŒã ã®æ§ç¯ãç®çãšããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æ£è ã®ç·æ¥åºŠã»éç床ãæ²»çæ¹éçãææ¡ã,æéåäœã®åŠæ¹ãå¯äœçšããµããŒ
ã(ææ¡ã»çžè«ã»åŠæ¹éæ»)ã³ã¹ããåãéããªã¹ã¯ãèæ ®ãé©æ£ã«å»è¬å管ç
(æ¥æ¬èšåºææ¥åŠäŒ ææ¥èªå®è¬å€åž«)
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æ©ææ²»çç(åšé¢æ¥æ°)é節å¯äœçšçºççåçŸæ£æªåçã€ã³ã·ãã³ãçºçç
ããã»ã¹è©äŸ¡ çµè žæ é€å®æœç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ã®å®æœãåžžé§åã¹ã¿ããã®é 眮
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ©ææ²»ççïŒåšé¢æ¥æ°ïŒã䜿çšè¬å€æ°ã»çšéã»æè¬æ¥æ°ãå䜵çã®çºççãé節
å¯äœçšã®çºççãæ¿ç®¡ã»é®éæ¥æ°ãQOL
ããã»ã¹è©äŸ¡ å°éã¹ã¿ããã«ããéäžçã±ã¢ãæ²»çå 容ã®èª¬æã»ç解ãå°éã¹ã¿ããã®å蚺
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ïŒåºãããã®å»çåŸäºè æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ ïŒäººåœããã®æ åœæ£è æ°ãåå°éè·çš®ã®å°éæ§
ããã»ã¹è©äŸ¡ åè·çš®ããã®çžè«åæ°ãã«ã³ãã¡ã¬ã³ã¹ãå匷äŒãžã®åå åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»åž«ã»çè·åž«ã® 24 æé察å¿ïœ€ã«ã³ãã¡ã¬ã³ã¹ãå匷äŒã®å®æœãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ åšé¢æ¥æ°ã»å¯äœçšçºççäœäžã«ããå»çã³ã¹ããã€ã³ã·ãã³ãåé¿ã«ããã³ã¹
ããäžèŠãªè¬å€æäžåé¿ã«ããè¬å€é¢é£ã³ã¹ã
ããã»ã¹è©äŸ¡ è¬å€äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥å»çã»éäžæ²»çå°ä»»è¬å€åž«ã®é 眮
å ·äœçãªææã»å¹æ 1) åžžé§ããå°ä»»è¬å€åž«ãæ£è ã®ç¶æ å€åãæ²»çæ¹éãVCMã®æäžèšç»ã«è¿ é
ã«åæ ããããšã§ãè¡äžæ¿åºŠæ²»çåã®ç¶æçãææã«é«ãä¿ãŠãïŒä»å ¥çŸ€ïŒ
61.7%ãéä»å ¥çŸ€ïŒ46.9%ãp=0.031)ãå°ä»»è¬å€åž«ã®ä»å ¥ã«ããäžæ¯å
ãžã®å°éãææã«äœäžããïŒä»å ¥çŸ€ïŒ2.3%ãéä»å ¥çŸ€ïŒ10.2%ãp=0.018 )ã
TDM å®æœçãäžæåŸåã«ãã£ãïŒä»å ¥çŸ€ïŒ89.6%ãéä»å ¥çŸ€ïŒ73.8%ã
p=0.059 )ã
2) åžžé§ããå°ä»»è¬å€åž«ã«ãã 6 ãæé㧠182 件ã®è¬ç©çæ³ãžã®ä»å ¥ãè¡ã£
ããåŠæ¹ææ¡ã 39 件ãšæãå€ãã次ãã§äžèŠãªè¬å€ã®äžæ¢ææ¡ã 31 件ã§
ãã£ãã
ææçãçºè¡šããåŠäŒ 1) å®èæ¬çã»ã, ææ¥ã»éäžæ²»çã«ããã VCM è¡äžæ¿åºŠç®¡çãžã®å°ä»»è¬å€åž«
ã®ä»å ¥å¹æ. 第 15 åæ¥æ¬èšåºææ¥å»åŠäŒç·äŒåŠè¡éäŒããã°ã©ã ã»æé²é,
194 (2012)
ææçãå ±åããè«æã»éèª 1) å®èæ¬çã»ã, ææ¥ïœ¥éäžæ²»çã«ããããã³ã³ãã€ã·ã³(VCM)è¡äžæ¿åºŠç®¡
çãžã®å°ä»»è¬å€åž«ã®é¢äž. æ¥èšæå»èª 16(4): 565ïŒ569 (2013)
28
ïŒæ¥åäŸ-â¡ïŒïŒïŒšïŒ©ïŒ¶ïŒ
ããŒã å HIV ææçããŒã
ããŒã ã圢æããç®ç
HIV ææçæ£è ã®æ§ã ãªåé¡ã解決ãæ²»çç¶ç¶ã§ãããããå€è·çš®é£æºã®ããš
å°éæ§ãçºæ®ããããŸããäžæ žæ ç¹ç é¢ãšããŠçå æœèšã«ããã蚺çã®åãŠã
åãå³ãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æ£è ãšé¢è«ãããã®æ å ±ãåºã«æ£è ãå»åž«ãšãšãã«æ²»çè¬ã決å®ãæè¬æå°ç¶
ç¶ãããã®éèŽåããæ å ±ãããŒã ã«ãã£ãŒãããã¯ãäœæ¶²æé²æã®ææäºé²
è¬ã®ç®¡çãïŒæ¥æ¬ç é¢è¬å€åž«äŒ HIV å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æ²»çæ瞟ã®åäž
ããã»ã¹è©äŸ¡ HIV-RNA é
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ HIV-RNA éãCD4 éœæ§ãªã³ãçæ°
ããã»ã¹è©äŸ¡ HIV ææçå°éè¬å€åž«ã«ããæè¬æå°ã®å®æœãæ£è ã®è¬ç©çæ³ã«å¯Ÿããç解床
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ HIV ææçå°éè¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§åäž
ããã»ã¹è©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ãå匷äŒã»åŠäŒãžã®åå åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ èªæœèšã»çå ä»æœèšã»è¡æ¿ã®çµæžçæ倱
ããã»ã¹è©äŸ¡ HIV ææçå°éè¬å€åž«ã«ããèªæœèšã»ä»æœèšã¹ã¿ãããè¡æ¿ãžã®æ å ±æäŸ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ èªæœèšã»ä»æœèšã®é¢å ææäºé²ããã¥ã¢ã«æŽåã«ããè¡æ¶²æé²æã®ææäºé²è¬
ã®å¹ççãªé 眮
å ·äœçãªææã»å¹æ 1) ä»é¢ã§ã¯å蚺ããªããªãæ£è ãå¿ ãååšããããåœé¢ã§ã¯å šå¡ã®æ£è ãç¶
ç¶å蚺ãããŠãããã»ãšãã©ã®æ£è ãã¢ããã¢ã©ã³ã¹è¯å¥œã§ããã
2) é¢å ä»ç§å ¥é¢æãå»çã¹ã¿ããã¯æé²æã®å¯Ÿå¿ãæ©æ¥ã«è¡ããäœå¶ãšãªã£
ãŠãããããå®å¿ããŠå»çè¡çºãè¡ããã
3) ä»é¢ã§ã®äœæ¶²æé²æã®å¯Ÿå¿ãæ©æ¥ã«è¡ããäœå¶ãšãªã£ãŠãããããå®å¿ã
ãŠæ£è ã®èšºçãè¡ããã
ææçãçºè¡šããåŠäŒ 1) äºéæ¬åã»ã, HIV ææçã«ãããããŒã å»çã®ç¢ºç«, æ¥æ¬è¬åŠäŒç¬¬ 123
å幎äŒèŠæšé, 4-144 (2003)
2) äºéæ¬åã»ã, HIV ææçåŠå©Šã®åºç£ã«ãããè¬å€åž«ã®åœ¹å², 第 17 åæ¥æ¬
ãšã€ãºåŠäŒèŠæšé, 390 (2003)
3) äºéæ¬åã»ã, æåªçã«ãããå»çåŸäºè ã® HIV ææäºé²ã«é¢ããå®æ 調
æ», 第 80 åæ¥æ¬ææçåŠäŒè¥¿æ¥æ¬å°æ¹äŒåŠè¡éäŒèŠæšé, 131 (2010)
ææçãå ±åããè«æã»éèª 1) äºéæ¬åã»ã, HIV ææçããŒã å»çã«ãããè¬å€åž«ã®åœ¹å².æ¥ç è¬èª
39(3): 319-321ïŒ2003ïŒ
2) äºéæ¬åã»ã, HIV ææçã®ããŒã å»çã«ãããè¬å€åž«ã®åœ¹å².è¬åŠéèª
126(6): 409-414 (2006)
29
ïŒæ¥åäŸ-â¡ïŒïŒïŒšïŒ©ïŒ¶ïŒ
ããŒã å HIV 蚺çããŒã
ããŒã ã圢æããç®ç
HIV 蚺çã«ãããŠãæ£è èªèº«ãæè¬ãå«ãèªå·±ç®¡çããèªèº«ã®å¥åº·ãåäžã»ç¶
æã§ããããã«ãªãããšã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
HIV ææçã«ãããè¬ç©çæ³ã«ãããŠãé«åºŠãªç¥è,æè¡,å«ç芳ãåããæ£è
ã®ææãå°éããè¬ç©çæ³ãæå¹ãã€å®å šã«è¡ããïŒæ¥æ¬ç é¢è¬å€åž«äŒ HIV
å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ã¢ããã¢ã©ã³ã¹åäžã»ç¶æããšã€ãºçºçç
ããã»ã¹è©äŸ¡ å°éè¬å€åž«ã«ããæ HIV è¬ã®æè¬æå°åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°éè¬å€åž«ã®é 眮
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ HIV-RNA éãCD4 æ°ãå¯äœçšãã¢ããã¢ã©ã³ã¹åäžã»ç¶æ
ããã»ã¹è©äŸ¡ æ HIV è¬ã®ç解ãå®æå蚺ã»æè¬ã®éµå®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°éè¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§åäžãè² æ 軜æžå¹æ
ããã»ã¹è©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ãåè·çš®ããã®çžè«åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°ä»»å»åž«ãå°åŸçè·åž«ãå°ä»»è¬å€åž«ã瀟äŒçŠç¥å£«ã®é å±
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ HIV ããŒã å»çå ç®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°ä»»å»åž«ãå°åŸçè·åž«ãå°ä»»è¬å€åž«ã瀟äŒçŠç¥å£«ã®ç¢ºä¿ããã©ã€ãã·ãŒã®ä¿è·
ã«é æ ®ãã蚺å¯å®€ã»çžè«å®€ã®èšå¶
å ·äœçãªææã»å¹æ 2009 幎 4 æãããHIV å€æ¥æ£è ãžã®æè¬æå°ãããã«å å®ããããããå°é
å€æ¥ã«è¬å€åž«ãåžžé§ããããããã®çžè«å®€ããæ°èšãæ¥åãéå§ãããè¬å€åž«
ãå€æ¥ã«åžžé§ããããšã«ãããé¢è«æ£è æ°ã¯é£èºçã«å¢å ãã蚺çãšé£åãã
æè¬æå°ã«ãã£ãŠãå»åž«ã»çè·åž«ãšã®é£æºã®å å®ãæ£è ãè¬ã«å¯ŸããŠãçžè«ã
ãããç°å¢ãæŽåãããã
ææçãçºè¡šããåŠäŒ 1ïŒåéå®å®ã»ã, ä¿éºèª¿å€è¬å±ãšã®é£æº.第 22 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒã·ã³ã
ãžãŠã è¬æŒèŠæšé, 234 (2012)
2ïŒåéå®å®ã»ã, è¬å€åž«å€æ¥ã®åãçµã¿-HIV ããŒã å»çã«ãããè¬å€åž«ã®åœ¹
å²-. æ¥æ¬è¬åŠäŒç¬¬ 132 幎äŒè¬æŒèŠæšé (2012)
3) åéå®å®ã»ã, HIV ææç蚺çã«ããã è¬å€åž«ã®åœ¹å².æ¥æ¬è¬åŠäŒç¬¬ 133
å幎äŒã·ã³ããžãŠã è¬æŒèŠæšé (2013)
ææçãå ±åããè«æã»éèª 1) Yoshino M et al., Assessing recovery of renal function after tenofovir
disoproxil fumarate discontinuation. J Infect Chemother 18(2):
169-174 (2012)
2) åéå®å®ã»ã, åœé¢ã«ãããïŒæ¥ïŒåæäž ãã«ããã«/ãªãããã«ã®äœ¿çš
æ瞟.æ¥æ¬ãšã€ãºåŠäŒèª 14(3): 141-145 (2012)
3) åéå®å®ã»ã, HIV ææçå°éè¬å€åž«ã®åœ¹å². è¬äºæ°å ±, 2741: 15-20
(2012)
30
ïŒæ¥åäŸ-â¢ïŒïŒç·©åïŒ
ããŒã å ããŒã YURCC (Yamagata University hospital team Renal Cell Cancer treatment)
ããŒã ã圢æããç®ç
è 现èçã«å¯Ÿããååæšçè¬æ²»çãå®å šã«è¡ãããã«ãååæšçè¬ã«ããæ²»çã
å¯äœçšãããžã¡ã³ãã®çµéšãèç©ã»å ±æããæ®éåããããšãç®çãšããŠããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æè¬æå°ãéããŠæ£è æè²ãè¡ããå¯äœçšã®ãããã¡ã€ãªã³ã°ãè¡ããå¹çç
ã«æ£è æ å ±ãããŒã ã«äŒããã(æ¥æ¬ç·©åå»çè¬åŠäŒ ç·©åè¬ç©çæ³èªå®è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ å¯äœçšäºé²ãæ©æçºèŠïœ¥å¯ŸåŠããããã®æ£è æè²ã»æå°ããããžã¡ã³ãæ³ã®å®æœ
ããã»ã¹è©äŸ¡ æ©æããã®ä»å ¥ãå¯äœçšçºçŸãéç床
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããŒã å ã§æ å ±ãå ±æããããã®ããŒã«ãããã±ãŒãžå
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å¯äœçšãäºé²ã»æ©æçºèŠãQOL
ããã»ã¹è©äŸ¡ æ£è æè²ãå¯äœçšåæçç¶ã®ç解ãæ£è æ å ±å ±æãæäžã¹ã±ãžã¥ãŒã«ã®ç解
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»çåŸäºè ã»æ£è é¢ä¿ã®ç¢ºç«
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ å ±å ±æã®æ段ã®æ§ç¯
ããã»ã¹è©äŸ¡ ããŒãã£ã³ã°ã®å®æœãããŒã å ã®å®æçãªã¡ãŒã«ãã¬ãžã³éä¿¡çã®å®æœ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ä»æœèšãžã®æ å ±æäŸ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ å®äŸ¡ã§å¹æçãªè¬å€äœ¿çšã«ããå¯äœçšå¯Ÿçãå¯äœçšæã«äœ¿çšããè¬å€è²»
ããã»ã¹è©äŸ¡ ã¹ã¿ãããžã®åšç¥
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ç æ£æ åœè¬å€åž«ããšããã³ã¹ã®æ€çŽ¢ãç 究ãæ å ±æäŸ
å ·äœçãªææã»å¹æ 1)ãæ足çå矀ã®äºé²ãæ足çå矀ã«å¯ŸããŠå€çšå€ãçšããäºé²çä»å ¥ãè¡ã£
ãããã®çµæãä»å ¥ã«ããææã«çºçŸãæå¶ããããšãã§ããã
2)ãå£å çã®äºé²ããšãããªã ã¹ã®å£å çã«å¯Ÿããã¢ãºã¬ã³ã¹ã«ãã³é žå«åœã«
ããäºé²çä»å ¥ãå®æœãä»å ¥çŸ€ã®å£å ççºçŸçã¯ææã«äœäžãããä»å ¥ãç¶
ç¶ãé·ææçšäŸãèªããããããã«ãªã£ãã
3)ãåçš®ããŒã«ã®äœæããYURCC ããã±ãŒãžããäœæããŠæŽ»çšããŠãããçŸå Ž
ã®çµéšãææ°ã®ãšããã³ã¹ãããããŠå®æçã«ã¢ããããŒãããŠãããé¢
å ãä»é¢ãžã®æ å ±æäŸãè¡ãªã£ãŠããã
ææçãçºè¡šããåŠäŒ 1) å¿ç°æå®ã»ã, ååæšçè¬æ²»çããŒã "YURCCâã«ãããè¬å€åž«ã®æŽ»å. 第
40 åè çç 究äŒïŒè çç 究äŒäŒå ± (40): 60 (2011)
2) å¿ç°æå®ã»ã, ã¢ãºã¬ã³å«åœã«ãããšãããªã ã¹ã®å£å ççºçŸäºé²å¹æ.
第 21 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 157 (2011)
3) å¿ç°æå®ã»ã, è 现èããã«å¯Ÿããååæšçè¬ã®å£å ççºçŸã«å¯Ÿããäºé²
çä»å ¥. 第 17 åæ¥æ¬ç·©åå»çåŠäŒå¹ŽäŒèŠæšé, 479 (2012)
4) å¿ç°æå®ã»ãïŒã¢ãã·ãããã«ããå£å ççºçŸå åã®æ€èš. 第 52 åæ¥æ¬è¬
åŠäŒæ±åæ¯éšå€§äŒèŠæšéïŒ78ïŒ2013ïŒ
ææçãå ±åããè«æã»éèª 1) å¿ç°æå®ã»ã, ååæšçè¬æ²»çããŒã "YURCC"ã«ãããè¬å€åž«ã®æŽ»å, æ³
å°¿åšå€ç§ 24(å¢å 2): 796-797 (2011)
2) å¿ç°æå®ã»ãïŒãã«ããããŒãŒé»å®³å€ã®æ足çå矀çºçŸã«å¯Ÿããå°¿çŽ è»è
ããã³ãããªã³é¡äŒŒç©è³ªå«æè»èå¡åžã«ããäºé²å¹æã®æ¯èŒ æ¥ç è¬èª
49(12): 1293-1298 (2013)
31
ïŒæ¥åäŸ-â¢ïŒïŒç·©åïŒ
ããŒã å ç·©åã±ã¢ããŒã
ããŒã ã圢æããç®ç
æ£è åã³å®¶æã«å¯ŸããçŸæ£ã®çã¿ã身äœçåé¡ãå¿ç瀟äŒçåé¡ãã¹ããªãã¥
ã¢ã«ãªåé¡ã®è©äŸ¡ãè¡ããé害ãšãªããªãããã«äºé²ããã察åŠãããããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬å€ã®æ å ±ïŒè¬ã®äœçšæ©åºã»å¯äœçšã»çžäºäœçšã»é©åãªè¬å€ã®ææ¡çïŒæäŸã
æ£è ã»å®¶æã«å¯Ÿããæå°ãå»ççšéº»è¬ã®æ å ±æäŸãåšå® å»çã«é¢ããé£æº
ïŒæ¥æ¬ç·©åå»çè¬åŠäŒ ç·©åè¬ç©çæ³èªå®è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æ£è ã»å®¶æã®ããŸããŸãªèŠçã®ç·©å
ããã»ã¹è©äŸ¡ çŒçç·©åãå¯äœçšå¯Ÿçã粟ç¥çç·©å
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ç·©åã±ã¢ããŒã ã®ããŒãã£ã³ã°ãšå®æçã©ãŠã³ãã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ©æã®èº«äœççŒçç·©å
ããã»ã¹è©äŸ¡ å»çã¹ã¿ãããžå»ççšéº»è¬ã®æ£è ã«ããèªå·±ç®¡çã®åè
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»ççšéº»è¬ã®æ£è ã«ããèªå·±ç®¡ççã®åäž
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ 䞻治å»ãžã®è² æ 軜æž
ããã»ã¹è©äŸ¡ å®æçã©ãŠã³ãã®å®æœ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ£è æ å ±ã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ ç·©åã±ã¢èšºçå ç®ç®å®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ç·©åã±ã¢ããŒã ä»å ¥ä»¶æ°
å ·äœçãªææã»å¹æ æ©æã®èº«äœççŒçç·©åããããåœé¢ç·©åã±ã¢ããŒã ã§ã¯ãæ£è ã«ããå»ççšéº»
è¬ã®èªå·±ç®¡çãåºæ¥ãããã«æšå¥šããŠãããããã§ãç·©åã±ã¢ãªã³ã¯ããŒã¹ãž
ã®åŠç¿äŒã§çŒçã±ã¢ã®æ£ããç¥èçãæäŸãããšãããç æ£ã§ã®èªå·±ç®¡ççãã
2011 幎 4 æ 30ïŒ ã11 æ 43.4ïŒ ãšåäžããŠããã
ææçãçºè¡šããåŠäŒ 1) å¿ç°æå®ã»ã, å»ççšéº»è¬èªå·±ç®¡çã«å¯Ÿããæè調æ»ã®å ±å. 第 5 åæ¥æ¬
ç·©åå»çè¬åŠäŒå¹ŽäŒããã°ã©ã ã»èŠæšé, 177 (2011)
2) 鹿éãããã»ã, å»ççšéº»è¬èªå·±ç®¡ççã®æšé²ãšçè·åž«ã®æèå€å. 第 17
åæ¥æ¬ç·©åå»çåŠäŒèŠæšé, 407 (2012)
32
ïŒæ¥åäŸ-â¢ïŒïŒç²Ÿç¥ïŒ
ããŒã å ã»ã«ãã±ã¢ããã°ã©ã æ åœããŒã
ããŒã ã圢æããç®ç äŒè·äžã埩è·åžæã®æ£è ã®æ¯æŽãããããå€è·çš®ã«ããããã°ã©ã ãè¡ãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
æè¬ã«å¯Ÿããäžå®ã»çåã®è§£æ¶ãæè¬ã¢ããã¢ã©ã³ã¹ã®ç¶æãšåäž
ïŒæ¥æ¬ç é¢è¬å€åž«äŒ 粟ç¥ç§å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ãã€ç ã®è©äŸ¡å°ºåºŠ
ããã»ã¹è©äŸ¡ çŸæ£æè²ã»èªç¥è¡åçæ³ã»æè¬åŠç¿ã»å°±åŽæ¯æŽãåäžããã°ã©ã ã§å®æœ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ 粟ç¥ç§è¬ç©çæ³èªå®è¬å€åž«ã»ç²Ÿç¥ç§å°éè¬å€åž«ã®é 眮
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æãã€è¬ã»ç¡ç å°å ¥å€ã®æè¬éµå®
ããã»ã¹è©äŸ¡ è¬ç©çæ³ã®éèŠæ§ã®ç解
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å€è·çš®ã«ããé¢ãããæ£è å士ã®æ å ±å ±æ
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å ±ææ å ±ã®ããã°ã©ã ãžã®åæ
ããã»ã¹è©äŸ¡ äŒè°ã®å®æœã»æ å ±å ±æ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ 1 åã®äŒè°
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»çè²»ã»ç€ŸäŒä¿éè²»æå¶
ããã»ã¹è©äŸ¡ æè¬ç¶ç¶ã«ããç ç¶æªåã»å ¥é¢ã®äºé²ã埩è·ã»åå°±è·
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å€è·çš®ã«ããé£æº
å ·äœçãªææã»å¹æ 1) æ£è ã®ã¢ã³ã±ãŒãã«ãããšãæãã€è¬ã»ç¡ç è¬ã«å¯Ÿããäžå®ãããã°ã©ã
åããæžå°ããçŸæ£ã«ã€ããŠç解ã§ããã
2ïŒåè©äŸ¡å°ºåºŠïŒæãã€å°ºåºŠ BDI-IIãèªå·±å¹åæ尺床 GSESã瀟äŒåŸ©åž°å°ºåºŠ
SASSïŒã«ãã㊠8 å²ä»¥äžã®æ£è ã«æ¹ååŸåãèŠãããã
3ïŒæ£è ãæ±ãã瀟äŒå¶åºŠããã³å°±åŽæ¯æŽãææ¡ããããšã«ããç é¢å å€ãžã®
å¿ èŠéšéãžã®æ å ±æäŸãè¡ãæ§ç¯ãåºæ¥ãããŸããçµæžçã«å°çª®ãå€æ¥æ²»
çäžæãããããã®ããæ£è ãæªç¶ã«é²ãããšãã§ããã
ææçãçºè¡šããåŠäŒ 1) é«æ©æºéã»ã, 埩è·æ¯æŽãã»ã«ãã±ã¢ããã°ã©ã ãã«ãããè¬å€åž«ã®é¢ãã.
第 39 åæ¥æ¬ç²Ÿç¥ç§ç é¢åäŒç²Ÿç¥å»åŠäŒèŠæšé, 225 (2011)
2) åå·è²Žä¹ã»ã, ä»è·çš®å ±åã«ããã»ã«ãã±ã¢ããã°ã©ã ã®è©Šã¿âäºäŸãã
èŠãä»åŸã®å±æâ. 第 39 åæ¥æ¬ç²Ÿç¥ç§ç é¢åäŒç²Ÿç¥å»åŠäŒèŠæšé, 225
(2011)
3ïŒåå·è²Žä¹ã»ã, ä»è·çš®å ±åã«ããã»ã«ãã±ã¢ããã°ã©ã ã®å®è·µå ±å.第 42
ååæµ·éäœæ¥çæ³å£«åŠäŒèŠæšé, 91 (2011)
33
ïŒæ¥åäŸ-â¢ïŒïŒïŒšïŒ©ïŒ¶ïŒ
ããŒã å HIV ã±ã¢ããŒã
ããŒã ã圢æããç®ç
HIV/AIDS ãããã¯æ ç¹ç é¢ãšããŠãé«åºŠãªãšã€ãºå»çã®æäŸããã³ãããã¯
å ã®ãšã€ãºå»çã®æ°Žæºã®åäžã»å°åæ Œå·®ã®æ¯æ£ãžã®æ¯æŽ
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
æè¬æŽå©ãè¬å€éžæã»åŠæ¹èšèšã»å€æŽã®ææ¡ãæ°æ å ±ã®åéã»æäŸãåè·çš®ç
ä¿®äŒå®æœãé¢å å€çäŸæ€èšïŒæ¥æ¬ç é¢è¬å€åž«äŒ HIV ææçå°éã»èªå®è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ãšã€ãºé¢é£çŸæ£ã®çºççãå䜵ççºçŸçããšã€ãºé¢é£çŸæ£ã«ããæ»äº¡ç
ããã»ã¹è©äŸ¡ HIV-RNA éãæ¥åèŠææçã»å䜵ççºçŸçãåè·çš®ã®ç ä¿®äŒéå¬åæ°ãä»æœ
èšãžã®å»çããŒã 掟é£åæ°ã
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ããŒã ã«ã³ãã¡ã¬ã³ã¹ã®å®æœãåå°éè·ã®é 眮ãä»æœèšããã®çžè«äœå¶å å®
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ éé¢ã»æè¬ç¶ç¶çããŠã€ã«ã¹éæ€åºéçç¶æãå䜵ççºçŸç
ããã»ã¹è©äŸ¡ ããŒã ã®å°éè·ã«ããé¢è«åæ°ãæ£è ã®æ²»çå 容ã®ç解
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ åå°éè·ã®ã¹ã¿ããæ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«èšºçæéççž®ãåœé¢ã»ãããã¯å ã®åå°éè·çš®ã®å°éæ§ïŒæ¥æ¬ç é¢è¬å€åž«
äŒïŒšïŒ©ïŒ¶ææçå°éã»èªå®è¬å€åž«ã®èªå®ååŸïŒ
ããã»ã¹è©äŸ¡ è¬å€åž«é¢è«å®æœçãå€è·çš®éçžè«åæ°ãã«ã³ãã¡ã¬ã³ã¹ã»ç ä¿®äŒåå åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æ£è ã®åé¡ç¹ã»æ²»çæ¹éã®å ±æãã«ã³ãã¡ã¬ã³ã¹å®æœãåå°éè·ç ä¿®äŒã®å®æœ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ ãŠã€ã«ã¹çŸæ£æå°æïŒã®ç®å®
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ åå°éè·ã®é 眮
å ·äœçãªææã»å¹æ è¬å€åž«ã«ããå šæ£è ãžæè¬æŽå©ãå®æœããã2013 幎 4 ææç¹ã§æ HIV çæ³æœ
è¡äž 117 åã®å ,æè¬äžæ 1 åããŠã€ã«ã¹éæ€åºéç以äžçŽ 75%ã200 ã³ããŒ
以äžçŽ 20%ã200 ã³ããŒä»¥äžã¯å šå¡æè¬éå§å幎以å ã§ãŠã€ã«ã¹åŠçæ²»ç倱
æäŸã¯ç¡ãããããã¯å æ ç¹ç é¢ããäŸé Œã®å šçäŸæ€èšãžããŒã ã®äžå¡ãšããŠ
掟é£ãåå°éè·ïŒè¬å€åž«ïœ¥å»åž«ïœ¥çè·åž«ïœ¥èšåºå¿ç士MSWïŒç ä¿®äŒãäŒç»ã»å®æœã
ææçãå ±åããåŠäŒçºè¡š 1) è€ç°ååã»ã, æ HIV è¬å€æŽã«ããè¬ç©çžäºäœçšãèæ ®ããæãŠãããè¬
ã®æäžèšèšãè¡ã£ãäžçäŸ.第 23 åæ¥æ¬ãšã€ãºåŠäŒåŠè¡éäŒã»ç·äŒæé²é,
582 (2009)
2) 倪åæå²åã»ã, åºå³¶å€§åŠç é¢ã«ãããã©ã«ãã°ã©ãã«ã®äœ¿çšç¶æ³ãšç²Ÿç¥
çç¶ã®å¯äœçšèª¿æ».第 24 åæ¥æ¬ãšã€ãºåŠäŒåŠè¡éäŒã»ç·äŒæé²é, 366
(2010)
3) è€ç°ååã»ã, åœé¢ã«ããã HIV ææè ã«å¯Ÿãã B åèçã¯ã¯ãã³æ¥çš®
ã®å¹æã«ã€ããŠ, 第 86 åæ¥æ¬ææçåŠäŒç·äŒåŠè¡è¬æŒæé², 383 (2012)
ææçãå ±åããè«æã»éèª 1) éœè€èª åžã»ã, HIV/HBVéè€ææçäŸã«ãããHBVã«å¯Ÿããæ²»ççµéšãšã
ã®èå¯.æ¥æ¬ãšã€ãºåŠäŒèª 14(2): 111-117 (2012)
2) è€äºèŒä¹ ã»ã, äžåœååœãããã¯ã«ããã HIV å»çäœå¶ã®æŽåã«é¢ããç
究.å¹³æ 24 幎床åçåŽåç§åŠç 究費è£å©éãšã€ãºå¯Ÿçç 究äºæ¥å ±åæž,
60-73ïŒ2013ïŒ
3) çäºæµ©å.HIV ææçã®çŸç¶ãšè¬å€åž«ã®åœ¹å²,ãã¡ã«ãã·ã¢ 49(11): 1058-
1063 (2013)
34
ïŒæ¥åäŸ-â£ïŒïŒããïŒ
ããŒã å ããååŠçæ³å¯äœçšå¯Ÿå¿ããŒã
ããŒã ã圢æããç®ç
ç æ£åžžé§è¬å€åž«ãæ§ç¯ããã¬ãžã¡ã³æ¯ã®å¯äœçšäºæž¬ã·ã¹ãã ã«åºã¥ããæ£è ã
å«ããããŒã å šå¡ã§æ å ±ãå ±æããå®å šç®¡çãè¡ãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
ã¬ãžã¡ã³æ¯ã®å¯äœçšã®çºçŸææäºæž¬ãæè¬æå°ãé©åãªäºé²æ³ã®ç¢ºèªã»ææ¡ã
å¯äœçšã¢ãã¿ãªã³ã°ãå¯äœçšå¯Ÿçã®ç«æ¡ãåŠæ¹ææ¡ïŒæ¥æ¬å»çè¬åŠäŒ ããå°
éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ å¯äœçšäºæž¬çãå¯äœçšçºçŸçãæ²»çç¶ç¶ç
ããã»ã¹è©äŸ¡ å»çåŸäºè ããã®èª¬æåæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å¯äœçšäºæž¬ã·ã¹ãã ã®å°å ¥ãã«ã³ãã¡ã¬ã³ã¹ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ²»çç¶ç¶çãå¯äœçšçºçŸç
ããã»ã¹è©äŸ¡ å»çåŸäºè ããã®èª¬æåæ°ãæ²»çå 容ã®ç解床ãå»çããŒã ã«ããå蚺åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ 1 åºãããã®å»çåŸäºè æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åè·çš®ã®ç¥èåäž
ããã»ã¹è©äŸ¡ ããŒã å ã§ã®çžè«åæ°ãã«ã³ãã¡ã¬ã³ã¹ã®åå åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹ã®å®æœãæ²»çæ¹éã»å¯äœçšæ å ±ã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ 人å¡é 眮ã®å€å
ããã»ã¹è©äŸ¡ è¬å€äœ¿çšéé¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»åž«ãåŠæ¹ã«èŠããæé
å ·äœçãªææã»å¹æ åµå·£ãã TC çæ³ã«ãããå¯äœçšã®äºæž¬ç²ŸåºŠã¯ 82%ã§ãããæ£è ããå»çã¹ã¿
ãããžã®çç¶ã®é£çµ¡ãå»çã¹ã¿ããéã§ã®ç¶æ³å ±æãããåæ»ã«ãªã£ãã
ææçãçºè¡šããåŠäŒ 1) Ikesue H et al., ADR monitoring form: a useful tool for the efficient
pharmaceutical care on cancer chemotherapy. 40th ASHP Midyear
Clinical Meeting and Exhibition, 103 (2005)
2) æ± æ«è£æ. ããååŠçæ³ã¯ãŒã¯ã·ãŒãã®éçºãšè©äŸ¡ã«é¢ããç 究. 第 15 å
æ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 149 (2005)
3ïŒæ± æ«è£æã»ã. ããååŠçæ³ã«ãããå¯äœçšãžã®å¯Ÿå¿. 第 19 åæ¥æ¬å»çè¬
åŠäŒå¹ŽäŒè¬æŒèŠæšé, 227 (2009)
ææçãå ±åããè«æã»éèª 1) æ± æ«è£æã»ã. çååŠçæ³ã«ãããè¬å€ç®¡çæå°æ¥å-å¯äœçšã®çºçŸäºæž¬ã«
ãã質çåäžäžŠã³ã«å¹çå. æ¥ç è¬èª 38(7): 869-872 (2002)
2) Ikesue H et al., Monitoring for potential adverse drug reactions in
patients receiving chemotherapy. Am J Health-System Pharm 61(22):
2366-2369 (2004)
3) æ± æ«è£æ. ããååŠçæ³ã¯ãŒã¯ã·ãŒãã®éçºãšè©äŸ¡ã«é¢ããç 究. å»çè¬
åŠ 32(1): 1-12 (2006)
4) å ç°ãŸããã»ã. ååŠæŸå°ç·çæ³ã«ãããæ£è ç解床åäžã®ããã®æè¬æ
å°ã·ãŒãã®æ¹å. æ¥ç è¬èª 45(2): 247-250 (2009)
35
ïŒæ¥åäŸ-â£ïŒïŒææ¥ã»éäžïŒ
ããŒã å è¬å€åž«å°åŸäœå¶ã«ããææ¥ã»éäžæ²»çããŒã
ããŒã ã圢æããç®ç
è¬å€åž«ãåå ããææ¥å»çã«ç¹åããè¬åŠç管çãå»è¬åå®å šç®¡çãæäŸãã質
ã®é«ãè¬ç©çæ³ãã«è²¢ç®ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
å»è¬å管çãè¬ç©æ²»çæ¯æŽïŒåŠæ¹èšèšãTDM çïŒãå»è¬åå¯äœçšã®äºé²ã»è»œæž
察çãå»è¬åæ å ±æäŸãå»è¬åå®å šç®¡çïŒæ¥æ¬èšåºææ¥åŠäŒ ææ¥èªå®è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ éäžæ²»çå®€å ¥å®€æ¥æ°ãå»è¬åé¢é£ã€ã³ã·ãã³ãçºçç
ããã»ã¹è©äŸ¡ è¬å€ç®¡çæå°å®æœçãïŒå®æœçãã€ã³ã·ãã³ããžã®å¯Ÿçç«æ¡åæ°ãå¯äœçš
äºé²ã»è»œæžå¯Ÿç件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æåœææ¥ã»ã³ã¿ãŒãžã®ïŒææ¥èªå®ïŒè¬å€åž«ã®é 眮ãçäŸã«ã³ãã¡ã¬ã³ã¹åã³å®
å šç®¡çã«ã³ãã¡ã¬ã³ã¹ã®å®æéå¬
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ éäžæ²»çå®€å ¥å®€æ¥æ°
ããã»ã¹è©äŸ¡ ïŒææ¥èªå®è¬å€åž«ã«ããïŒè¬å€ç®¡çæå°å®æœãæ£è ãžã®é©æ£æè¬éã®èšå®ãå¯
äœçšã®äºé²ã»è»œæž
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æåœææ¥ã»ã³ã¿ãŒãžã®ïŒææ¥èªå®ïŒè¬å€åž«ã®é 眮ã1 åºåœãã®è¬å€åž«æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å»åž«ã®é©æ£æè¬éèšå®åã³è¬åéžæã«èŠããæéãçè·åž«ã®å»è¬åç解ãåå°
éè·çš®ã®å°éæ§ãå»è¬åæ å ±åéã®å¹çå
ããã»ã¹è©äŸ¡ ä»è·çš®ã®è³ªçå¿çã»ææ¡ä»¶æ°ãã«ã³ãã¡ã¬ã³ã¹éå¬ç¶æ³ãæåè¬éå¥ä»¶æ°ïŒïŒ®
ïœã®è² æ 軜æžïŒãè¬æ¯ç©äžæ¯åã³å»è¬åæ å ±æäŸä»¶æ°ïŒå»åž«ã®è² æ 軜æžïŒ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æåœææ¥ã»ã³ã¿ãŒãžã®ïŒææ¥èªå®ïŒè¬å€åž«ã®é 眮ãå®æçãªçäŸã«ã³ãã¡ã¬ã³
ã¹ã»å®å šç®¡çã«ã³ãã¡ã¬ã³ã¹ã®éå¬
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åç
ããã»ã¹è©äŸ¡ è¬å€ç®¡çæå°ç®å®ä»¶æ°ãé 眮è¬ã®åç®ã»æ°éïŒéé¡ïŒ
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ æåœææ¥ã»ã³ã¿ãŒãžã®ïŒææ¥èªå®ïŒè¬å€åž«ã®é 眮
å ·äœçãªææã»å¹æ æåœææ¥ã»ã³ã¿ãŒã«ãããŠãïŒã«ããæïŒïŒ²ïŒ³ïŒ¡æ³šå°è¬ã®è¡äžæ¿åºŠã®é©æ£
åãè æ©èœäœäžæã®å»è¬åã®é©æ£æäžéã®èšå®çã®è¬åŠç管çãè¡ã£ããçºç
ããå»è¬åé¢é£ã€ã³ã·ãã³ãäºäŸãåæããŠå æè¬ã»æ³šå°è¬ã®æè¬ããã¥ã¢ã«
ã®æ¹èšãè¡ã£ããçµæãšããŠãæåœææ¥ã»ã³ã¿ãŒã®å»è¬åé¢é£ã€ã³ã·ãã³ãã¯
å¹³æ 17 幎床㮠111 件ããå¹³æ 21 幎床ã«ã¯ 37 件ãžãšçµæçã«æžå°ããã
ææçãçºè¡šããåŠäŒ 1) å·ç° æ¬ã»ã, æåœææ¥ã»ã³ã¿ãŒã«ãããå»è¬åå®å šç®¡çãžã®è¬å€åž«ã®å
ãçµã¿. 第 11 åæ¥æ¬èšåºææ¥å»åŠäŒè¬æŒèŠæšé, 255-255 (2008)
2) ç°äž è¡ã»ã, é«ç¥å»çã»ã³ã¿ãŒã«ãããéäžæ²»ç宀ã§ã®è¬åŠç管çæå°.
第 18 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 386-386 (2008)
3) ç°äž è¡ã»ã, ææ¥å»çã«ãããå°ä»»è¬å€åž«ã«ããå»è¬åå®å šç®¡ç. 第 16
åæ¥æ¬èšåºææ¥å»åŠäŒè¬æŒèŠæšé, 301-301 (2013)
ææçãå ±åããè«æã»éèª 1) å·ç° æ¬ã»ã, æåœææ¥ã»ã³ã¿ãŒã«ãããå»è¬åå®å šç®¡çãžã®è¬å€åž«ã®è²¢
ç®. æ¥ç è¬èª 48(2): 181ïŒ184 (2012)
36
ïŒæ¥åäŸ-â£ïŒïŒææ¥ã»éäžïŒ
ããŒã å ææ¥ã»éäžæ²»çã±ã¢ããŒã
ããŒã ã圢æããç®ç æ£è ã®æ²»çã«æ倧ã®å¹æãçºæ®ãããã€å®å šãªå»çãæäŸãã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
è¬ç©æ²»çã®è©äŸ¡ãå¹æã»å¯äœçšã¢ãã¿ãªã³ã°ãåŠæ¹èšèšãTDMãæåè¬ç¢ºèªã
é 眮è¬ã®ç®¡çãåæ»ãªè¬å€äŸçµŠããªã¹ã¯ãããžã¡ã³ã ïŒæ¥æ¬èšåºææ¥å»åŠäŒ
ææ¥èªå®è¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ ICU å ¥å®€æ¥æ°ãMRSA æ€åºçãVAP çºççãè¬å€æäžæ¥æ°
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããè¬ç©çæ³é©æ£åãåè·çš®ããã®åãåãã件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ã«ã³ãã¡ã¬ã³ã¹åæ°ãã«ã³ãã¡ã¬ã³ã¹åºåžè·çš®
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æèè¬æäžæ¥æ°ãè¬å€è²»ãICU å ¥å®€æ¥æ°ãçåçãå ¥é¢æé
ããã»ã¹è©äŸ¡ è¬å€åž«ã«ããåŠæ¹ææ¡ä»¶æ°ãæ å ±æäŸä»¶æ°ãåè·çš®ããã®åãåãã件æ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ åè·çš®ã®åžžé§æéã人æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§åäž
ããã»ã¹è©äŸ¡ åè·çš®ããã®çžè«åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ èšåºæ€æ»æåž«ïŒ365 æ¥ 24 æéåžžé§ãã«ã³ãã¡ã¬ã³ã¹ã«ãŠæ²»çæ¹éå ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ£è å転çã皌åç åºæ°
ããã»ã¹è©äŸ¡ è¬å€è²»ãå ¥é¢è²»
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ææ¥ã»éäžæ²»çå°åŸè¬å€åž«ã®é 眮
å ·äœçãªææã»å¹æ
1) å ¥å®€æ¥æ°ã»æèè¬äœ¿çšæ¥æ°ã¯ãè¬å€åž«åžžé§åŸã§ææã« ICU å ¥å®€æéãåºå
æèè¬ã®æäžæ¥æ°ã®ççž®ãèªãããçåã¹ãã¯ãã©ã ã®æèè¬ã®æäžæ¥æ°
ã¯å€ãããªãã£ãã
2) è¬å€åž«åžžé§ãšãªããç¶æçã«è¬å€åž«ããã®åŠæ¹ææ¡ïŒå€æŽïŒä»¶æ°ã¯äžæãã
40 件/æã§ç¶æãããã
3) è¬å€åž«åžžé§ïŒå¹Žç®ãšïŒå¹Žç®ã§ã¯è¬å€åž«ã«ããå¯äœçšãªã¹ã¯ïŒé åå€åãçž
äºäœçšãè æ©èœäœäžã«ããééæäžãªã©ïŒãåé¿ãã件æ°ãïŒå¹Žç®ã§ææã«
äžæããã
ææçãçºè¡šããåŠäŒ
1) å è€éå¯ã»ã, å»åž«ãçè·åž«ããæåŸ ããã ICU/CCU åžžé§è¬å€åž«ã®åœ¹å²,
第 19 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 275, 2009
2) è©åççã»ã, ICU/CCU ã«ãããææçæ£è ã«å¯Ÿããè¬å€åž«ã®é¢ãã, 第
19 åæ¥æ¬å»çè¬åŠäŒå¹ŽäŒè¬æŒèŠæšé, 257, 2009
3) è©åççã»ã, ICU/CCUã«ãããææçæ£è ã«å¯Ÿããè¬å€åž«ã®é¢ãã,æ¥æ¬
ååŠçæ³åŠäŒéèª, 58 suppl. A: 301, 2010
4) è©åççã»ã, ICU/CCU ã«ãããè¬å€åž«ã®é¢ãã,æ¥èšæå»èª, 13(2):
226, 2010
5) å è€éå¯ã»ã, ICU/CCU ã«ãããè¬ç©çæ³æ¯æŽã®å€å, æ¥èšæå»èª, 14
(2): 305, 2011
ææçãå ±åããè«æã»éèª 1) å è€éå¯ã»ã, Intensive Care Unit/Coronary Care Unit ã«ãããè¬å€åž«
æ¥åã®åãçµã¿. æ¥èšæå»èª 13(5): 596-603 (2010)
37
ïŒæ¥åäŸ-â£ïŒïŒãã®ä»ïŒ
ããŒã å é«ãªã³è¡çæ²»çè¬ã®é©æ£äœ¿çšæšé²ããŒã
ããŒã ã圢æããç®ç
å»åž«ãçè·åž«ãæ é€å£«ãšååããŠãªã³ã®ã³ã³ãããŒã«ãäžååãªæ£è ãæœåºãã
æ é€æå°ãæè¬æå°ãéããŠè¯å¥œãªãªã³ã®ã³ã³ãããŒã«ãè¡ããäºåŸã®æ¹åã
ç®çãšããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
ãªã³åžçå€ãã§ãã¯ã·ãŒããçšããé£äºæåç¶æ³åã³æè¬ç¶æ³ã®ç¢ºèªãé£äºã®
éã«èŠåã£ãé«ãªã³è¡çè¬ã®æè¬æå° ïŒæ¥æ¬è èç è¬ç©çæ³åŠäŒ è èè¬ç©
çæ³å°éè¬å€åž«ïŒ
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ è¡æ¶²åŠçæ€æ»å€ãã³ã³ãã©ã€ã¢ã³ã¹
ããã»ã¹è©äŸ¡ ãªã³åã³ i-PTH æ¹åçãæè¬é å®ç¶æ³
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è èç è¬ç©çæ³å°éè¬å€åž«ã®é 眮ãå匷äŒã®éå¬
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ è¡æ¶²åŠçæ€æ»å€ãã³ã³ãã©ã€ã¢ã³ã¹
ããã»ã¹è©äŸ¡ æ²»çå 容ãèªèº«ã®é£äºæåç¶æ³ã®ç解ããªã³åžçè¬ã®ã¢ããã¢ã©ã³ã¹åäž
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è èç è¬ç©çæ³å°éè¬å€åž«ã®é 眮
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ åå°éè·çš®ã®å°éæ§åäž
ããã»ã¹è©äŸ¡ åè·çš®ããã®çžè«åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å匷äŒã®å®æœãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ è²»çšå¯Ÿå¹æ
ããã»ã¹è©äŸ¡ æ€æ»å€ã®æšç§»ãè©äŸ¡
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ è èç è¬ç©çæ³å°éè¬å€åž«ãéæèªå®çè·åž«
å ·äœçãªææã»å¹æ 1) æ£è åã ã®é£äºã«èŠåã£ãæè¬æå°ãè¡ãããšã«ãããæ£è èªèº«ãé£äºå
ã³æè¬ã«ã€ããŠèãã¢ããã¢ã©ã³ã¹ãåäžããã
2) æè¬æå°ã«ããè¡æž äžã®ãªã³ããã³ i-PTH ã®æ¹åã確èªãããã
ææçãçºè¡šããåŠäŒ 1) äžç³åæš¹ã»ã, ãªã³åžçå€ã®ã¢ããã¢ã©ã³ã¹åäžãç®æããåãçµã¿. 第
5 åæ¥æ¬è ãšè¬å€ç 究äŒåŠè¡å€§äŒ (2011)
38
ïŒæ¥åäŸ-â¥ïŒïŒããïŒ
ããŒã å å€æ¥ååŠçæ³æ¯æŽããŒã
ããŒã ã圢æããç®ç
ååŠçæ³ãéé¢ã«ãŠåããæ£è ã«ã¯ã1ïŒæå¹æ§ãšå®å šæ§ã確ä¿ãããååŠç
æ³ãè¡ãããš 2ïŒååŠçæ³ã«ããå¯äœçšå¯Ÿçãå¿ èŠã§ãããå€æ¥ååŠçæ³å®€
ãããŠå»åž«ã®åŠæ¹ã«å¯Ÿãè¬å€åž«ããããã³ã«ç®¡çãè¡ãããšã¯ååŠçæ³ã®æå¹
æ§ãšå®å šæ§ã確ä¿ã§ãããå¯äœçšå¯ŸçãšããŠå»åž«ãçè·åž«ãšé£æºããšããªããã
è¬å€åž«ãæ£è ãžã®æ²»çå 容ã®èª¬æãšãšãã«å¯äœçšã«é¢ããæå°ãããŠæ¯æçæ³
ã®åŠæ¹ææ¡ãããããšã¯å¯äœçšã®è»œæžãå»åž«ã®æ¥åè² æ 軜æžã«è²¢ç®ã§ããã
ããŒã ã§ã®è¬å€åž«ã®åœ¹å²
ïŒèªå®ã»å°éè¬å€åž«ã®é¢äžïŒ
ååŠçæ³ã¬ãžã¡ã³ã®ç®¡çããããã³ã«ã«åºã¥ãåŠæ¹ç£æ»ãæ£è ãžã®æè¬æå°ã
å¯äœçšãšæå¹æ§ã®ã¢ãã¿ãªã³ã°ãååŠçæ³å€ã®ç¡è調補ãå»åž«ãçè·åž«ãžã®è¬
å€ã«é¢ããæ å ±æäŸã (æ¥æ¬ç é¢è¬å€åž«äŒ ããè¬ç©çæ³èªå®è¬å€åž«)
â å»çã®è³ª
ã¢ãŠãã«ã è©äŸ¡ æ²»çå®éçãã€ã³ã·ãã³ãçºç件æ°ãå¯äœçšçºçç
ããã»ã¹è©äŸ¡ ãããã³ã«å¯©æ»å®æœçããããã³ã«ç£æ»å®æœç
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å°éè·çš®ã®é 眮ãã«ã³ãã¡ã¬ã³ã¹ã®å®æœ
â¡ æ£è ã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ æ£è æºè¶³åºŠãå¯äœçšã®çºçç
ããã»ã¹è©äŸ¡ å°éè·çš®ã«ããæå°åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ 1 åºåœããã®å»çåŸäºè æ°
⢠å»çã¹ã¿ã
ãã®èŠç¹
ã¢ãŠãã«ã è©äŸ¡ å¯äœçšå¯Ÿçæå°ã®åœ¹å²åæ
ããã»ã¹è©äŸ¡ åè·çš®ããã®çžè«åæ°ãã«ã³ãã¡ã¬ã³ã¹ãžã®åå åæ°
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ ç·æ¥äœå¶ã®æç¡ãã«ã³ãã¡ã¬ã³ã¹ã®å®æœãæ²»çæ¹éã®å ±æ
⣠çµæžçèŠç¹
ã¢ãŠãã«ã è©äŸ¡ ç é¢åçã人å¡é 眮ã®å€å
ããã»ã¹è©äŸ¡ å¯äœçšå¯Ÿçãžã®å»çè²»
ã¹ãã©ã¯ãã£ãŒè©äŸ¡ å»åž«ã»è¬å€åž«ã»çè·åž«ä»¥å€ã®ã¹ã¿ããã®å°å ¥
å ·äœçãªææã»å¹æ 1) 1 ãµæåœããã®å€æ¥ååŠçæ³å®æœä»¶æ°ã¯å¹³å 456.8±15.5 件ã§ãããè¬å€
垫㯠100ïŒ ãããã³ã«ç£æ»ãè¡ã£ãŠããããã®ãã¡çŽ 22ïŒ ïŒå¹³å 101±6.1
件ïŒã«ççŸ©ç §äŒãå¿ èŠãª åŠæ¹ããã£ããççŸ©ç §äŒ åŸã®å€æŽã¯å¹³å
94.8±1.7ïŒ ã§ãããè¬å€åž«ããããã³ã«ç£æ»ãããŠççŸ©ç §äŒããããšã§å
åŠçæ³ã®æå¹æ§ãšå®å šæ§ã確ä¿ãããã
2) è¬å€åž«ãçè·åž«ãé£æºããŠæ£è ç¶æ ã®ææ¡ãå¯äœçšã¢ãã¿ãªã³ã°ãè¡ãã
æ¯æçæ³ãåŠæ¹ææ¡ãã件æ°ã¯ãæå¹³å 11±5.7 件ã§ãããæ¡æçã¯å¹³å
98.9±2.5 ïŒ ã§ãã£ããè¬å€åž«ä»å ¥åŸã¯æ¹ååŸåïŒ25 件ïŒ45.5ïŒ ïŒãäžå€ïŒ
29 件ïŒ52.7ïŒ ïŒãæªåïŒ1 件ïŒ1.8ïŒ ïŒã§ãããè¬å€åž«ã«ããæ¯æçæ³ã®åŠ
æ¹ææ¡ãå¯äœçšã軜æžãããå»åž«ã®è² æ 軜æžãšãªã£ãŠãããšèããã
ææçãçºè¡šããåŠäŒ 1) åç°å¹žåžã»ã, çµè žçè¡åŸè£å©ååŠçæ³ïŒXELOX çæ³ïŒã®å®éãšå¯äœçšèª¿
æ».第 50 åæ¥æ¬çæ²»çåŠäŒåŠè¡éäŒè¬æŒèŠæšé, 177 (2012)
2) å°æŽçŸçŽæµã»ã, å€æ¥ååŠçæ³å®€ã«ãããæ é€ã«ã³ãã¡ã¬ã³ã¹ã®å¹æ. 第
29 åéèçµè žæ é€åŠäŒåŠè¡éäŒè¬æŒèŠæšé (å°å·äž)
39
â £. ãããã«
å¹³æ 22 幎ã«çºåºãããå»æ¿å±é·éç¥ã«ã€ããŠãæ¥ç è¬ãšããŠã®è§£éãè¡ããããŒã å»çã®äžã§è¬å€
åž«ãã©ã®ããã«è²¢ç®ãã¹ããã«ã€ããŠãäžéšã®å ·äœäŸã亀ããªããèšèŒãããèšããŸã§ããªããå»æ¿
å±é·éç¥ã¯çŸè¡æ³ã®è§£ééç¥ã§ããããã®äžã§ã©ããŸã§ã¹ãã«ããã¯ã¹ãå¯èœãã«ã€ããŠã®è§£éã瀺
ãããã®ã§ãããåŸã£ãŠãçŸåšãæã è¬å€åž«ãç®æããŠããå°æ¥å±æããããã°ããŸã ãŸã éåã°ãš
ãããšããã§ãããããããè¬å€åž«æ¥åã®é£èºã«åããŠã®ã¯ã³ã»ã¹ããããšèãããããŸã§ãªãããª
ãã£ãé åãžã®æ¥åæšé²ãåŸæŒããããã®ãšå€æããããã«å¿ããŠããããšãšãããã
ãŸããããã«èšèŒãããŠããæ¥åãåå»çæ©é¢ã®å®æ ã«å³ãã圢ã§å¯èœãªéãå®è·µããããåªãã
ããšããããŒã å»çãé£èºçã«çºå±ãããããšã«ã€ãªãããã²ããŠã¯ãæ³æ¹æ£ã䌎ã次ã®ã¹ãããã«
åããããšãå¯èœãšãªããåå»çæ©é¢åºæã®åé¡ãšç®æãæ¹åãååã«èžãŸãã€ã€ã質ã®é«ãããŒã
å»çã®æ§ç¯ãæ±ããããã§ãããã
ãã®ããã«ã¯ãåå»çæ©é¢ã®è¬å€åž«ã¯æ¥åã®å¹çåã»åçåçã®æ¥åèŠçŽããè¡ããå šç æ£ãžã®è¬
å€åž«ã®é 眮ã«æ倧éã®åªåãããããšã倧åã§ãããäžæ¹ãç±³åœãšæ¯ã¹ãŠãç åºåœããã®è¬å€åž«æ°ã
å§åçã«å°ãªãç¶æ³ã§ããã®ã§ãè¬å€åž«æ°ã®å¢å ãå³ãå¿ èŠããããåå»çæ©é¢ã®åªåã«è² ããšãã
ã倧ããããæ¥ç è¬ãšããŠãæ倧éã®æ¯æŽãè¡ãæåã§ãããå»çã«ãããæ確ãªè²¢ç®ã瀺ããè¬å€
åž«ãããªããã°ãå®å šã§å®å¿ãªå»çã¯æãç«ããªããšä»è·çš®ã«è©äŸ¡ãããããæ¥åå±éããé¡ããã
ãã
ãŸããããŒã å»çã«è²¢ç®ããããã«ã¯å šåœã®è¬å€åž«ã®è³è³ªåäžãå¿ é ã§ãããïŒå¹Žå¶ã®è¬åŠçã茩
åºãããŠããä»æ¥ããããªãè¬å€åž«ã®é£èºãžã®æåŸ ã¯å€§ãããå»ç人ãšããŠãè±ããªã³ãã¥ãã±ãŒã·
ã§ã³åãšãåºãèŠéããã£ãŠããã質ã®é«ãè¬ç©æ²»çã«è²¢ç®ã§ããè¬å€åž«ãæ±ããããŠããããŸãã
質ã®é«ãããŒã å»çãæšé²ããããã«ã¯åå°éè¬å€åž«ããã³èªå®è¬å€åž«ããåã ã®åéã«ãããŠçœåŒ
è ãšããŠååã«åéãçºæ®ããããšãéèŠã§ããã
åå»çæ©é¢ã«é©ããããŒã å»çã®æšé²ã«ãªãäžå±€åãçµã¿ãæ£è ãžã®å®å šäžã€é©æ£ãªè¬ç©æ²»çãé
æã§ããããåå»çæœèšã®è¬å€éšéã§ã¯ãæ¬è§£éãšå®è·µäºäŸãåèã«ããŠããã ããããå šåœã®è¬å€
åž«ãèªå·±ã®å°æ¥ãžã®æããå±æãæã€ãšãšãã«ãç ãã人ã®å€§ããªæ¯ãã«ãªãå»ç人ãšããŠãæ£è ã®
é¡ãèŠããè¬å€åž«ãšããŠãåãåãããçæ¯ã«è¬å€åž«æ¥åã«å°å¿µããããšãå¿ããæåŸ ãããã
äžè¬ç€Ÿå£æ³äºº æ¥æ¬ç é¢è¬å€åž«äŒ
å¹³æïŒïŒå¹ŽïŒïŒæïŒïŒæ¥äœæïŒVer.1.0ïŒ
å¹³æïŒïŒå¹ŽïŒïŒæïŒïŒæ¥æ¹èšïŒVer.1.1ïŒ
å¹³æïŒïŒå¹Ž ïŒæïŒïŒæ¥æ¹èšïŒVer.2.0ïŒ
ãªããVer.2.0 ã§ã¯ã¿ã€ãã«ãèšè¿°å 容ãæ¹ãããããŸã§ã®ãæ¥æ¬ç é¢è¬å€åž«äŒã«ãã解éãšå ·äœ
äŸããããæ¥æ¬ç é¢è¬å€åž«äŒã«ãã解éãšå®è·µäºäŸãã«å€æŽããã
40
Recommended